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Abstract
Each year, 800,000 new patients are diagnosed with head and neck squamous cell
carcinoma (HNSCC), a majority of whom are treated with a combination of daily fractions of
radiation and weekly chemotherapy sessions for up to seven weeks. Current methods to evaluate
treatment response of individual patients are limited to anatomical measurements of tumor burden
using CT scan or MRI 4-8 weeks after completion of treatment. However, earlier knowledge of
radiation-response prior to or at early days after commencement of therapy can aid oncologist
with escalating and de-escalating treatment plans for exceptionally non-responding and
responding patients. Such a knowledge can be only be gained if proper understanding of
radiation-induced physiological and biomolecular changes is established and associated with
treatment response.
This dissertation presents two quantitative optical spectroscopic methods that can provide
snapshots of tumor physiology and biomolecular content which can be used as biomarkers of
treatment response. Because tumor hypoxia has been linked to poor treatment outcome, we
employed diffuse reflectance spectroscopy to measure vascular oxygen saturation. In chapter 2,
we first investigated the sensitivity of diffuse reflectance spectroscopy to tumor hypoxia and
determined that optical measurement of tumor vascular oxygen saturation is negatively correlated
with tumor hypoxia. In chapter 3, we utilized this technique to study radiation-induced kinetics of
tumor oxygenation among radiation-resistant and -sensitive tumors. We established tumor
xenografts from two human head and neck cancer cell lines in mice which were treated with 4
doses of 2 Gy twice weekly for two weeks. We observed greater rate of reoxygenation in radiationresistant tumors which was accompanied with greater content of hypoxia inducible factor-1α (HIF1α). Our results indicate that reduced oxygen consumption rate can potentially play a significant
role in promoting radiation resistance. In addition, the radiation-induced changes in tumor optical
properties were used to train a logistic regression model which successfully differentiated localcontrol and treatment-failure tumors.

In addition to changes in reoxygenation, radiation treatment has also been known to
induce microenvironmental changes within tumor. Thus in chapter 4, we used Raman
spectroscopy

to

investigate

early

radiation-induced

biomolecular

changes

in

tumor

microenvironment of radiation-resistant and -sensitive tumors. Raman spectra of head and neck
tumor xenografts 1, 24, and 48 hours after radiation was collected and the spectra were analyzed
using multivariate curve resolution-alternating least squares (MCR-ALS) and pure spectral
profiles of biological specimen were extracted. We observed higher contributions to Raman
spectra from lipid- and collagen-like species respectively in radiation-sensitive and -resistant
tumors. Our results indicate the sensitivity of Raman spectroscopy to radiation-induced
microenvironmental changes at early time points after radiation. The association between the
observed functional and biomolecular changes with the radiosensitivity of the utilized tumors
motivate further clinical studies to investigate whether such changes can be used as potential
biomarkers of radiation response.
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Chapter 1: Introduction
Introduction to head and neck cancer
Head and neck cancers encompass cancers of the oral and nasal cavity, pharynx, and
larynx. Because majority of head and neck cancer originate in epithelial layer of mucosal tissue,
the malignancy is typically referred to as head and neck squamous cell carcinoma (HNSCC) 1.
Repeated tobacco exposure and alcohol dependence are known to be substantial non-intrinsic
risk factors for HNSCC2. However, oncogenic viruses, such as human papillomavirus (HPV), also
play significant role in development of HNSCC3. Regardless, HNSCC is the sixth most common
cancer type with an annual ~800,000 new cases and ~400,000 deaths worldwide4 with 5th lowest
5-year survival rate of 65%. Over the past few decades HNSCC incidence has slightly reduced
primarily due to reduction in tobacco consumption and better patient management5. However, the
annual economic toll of HNSCC to U.S. economy is $14 billion with a median total cost of $80,000
per person6,7. Because of the high cost of cancer treatment, prevention, early detection, and
treatment response identification become more cost-effective, and potentially life-saving
strategies.
Cancer staging
According to American Joint Committee on Cancer (AJCC), cancer staging is based on
three factors – Tumor size and location, the extent of lymph Node involvement, and the degree
of Metastatic spread (TNM)8. Using TNM criteria, head and neck cancer is usually classified into
one of four major categories. Stage I cancers refer to primary tumors that are 2 cm or smaller and
remain in their original location. Stage II cancers are 2-4 cm and have not invaded nearby tissues,
lymph nodes, or distant sites. Stage III cancer, however, refers to tumors larger than 4 cm or
tumors smaller than 3 cm that have reached one lymph node. Finally, stage IV cancer can be
defined as tumors that have invaded the nearby tissue, have spread to one or more lymph nodes,
or to distant sites.
1

Treatment strategies
Stage I and II HNSCC patients are usually treated with surgery or radiation therapy.
Although tumor location can influence the choice of treatment, surgery is preferred at early stages
because it can avoid the toxic side effects of radiation1. Nevertheless, radiation treatment alone
can also be used as the sole strategy in combating stage I and II cancers. Using advanced
intensity-modulated radiation therapy that optimizes delivery of radiation to specific volumes,
radiation exposure to adjacent tissue can be minimized and toxic side effects on normal tissue
can be avoided9. Radiation for early stage cancer patients is usually delivered in daily fractions of
2.5 Gy for 6-7 weeks and has been shown to lead to promising results with no major toxic side
effects10. These treatment strategies in ~80% of early-stage cancer patients lead to complete
tumor remission.
However, locally advanced cancers (III and IV) are concurrently treated with daily fractions
of 2 Gy radiation combined with weekly doses of chemotherapy11. Cisplatin and Cetuximab are
widely combined with radiation-therapy for treatment of late stage HNSCC and have been shown
have similar and promising results in treatment of late stage HNSCC patients12. In patients with
resectable tumors, concurrent radiation and chemotherapy regimen is administered after surgery.
Nevertheless about 50% of patients with late stage disease experience locoregional recurrence
(III and IV)13,14.
Current clinical standard of care
Retrospective clinical studies have shown that Human Papilloma Virus (HPV) status is a
good indicator of prognosis, treatment response, and overall survival in HNSCC patients because
HPV+ patients show significantly better survival and response to radiation compared with HPVnegative patients15. Thus, for early stage HNSCC patients, endoscopic guided biopsy is routinely
performed with the goal of identifying HPV status of tumor, determining its radiosensitivity, and
deciding best treatment strategies (radiation or surgery). However, for late-stage cancer patients,
2

biopsies are not usually performed. Because in late-stage, cancer has already spread to nearby
tissue or distant site hence, treatment options become limited and patients undergo aggressive
treatment plans with the aim of halting tumor growth and spread. Furthermore, despite being
prognostically important, knowledge about HPV status does not lead to undertaking different
treatment approaches16. Thus, HPV status is not currently considered in treatment planning of
late-stage head and neck cancer patients.
Thus, current response evaluation metrics heavily rely on anatomical measurements of
tumor burden. In 2000, the National Cancer Institute in collaboration with several other
international organizations published a set of criteria that are used to evaluate a cancer patient’s
response to given treatment. Response evaluation criteria in solid tumors (RECIST) classifies
treatment outcomes to three main categories: complete response (CR) in which entire target
lesion disappears, partial response (PR) in which the longest diameter of target lesions have
decreased 30% or more, and progressive diseases (PD) in which the target lesion has
experienced a 20% or greater increase in the longest diameter of the target lesion 17. A fourth
category, stable disease (SD) also exists in which neither sufficient reduction or increase in the
longest diameter is observed to qualify for PR or PD. The RECIST guidelines utilize tumor growth
delay assay to monitor tumor burden regression by radiographic imaging as an important factor
in response evaluation of individual patients18. In particular, computed tomography (CT) and
magnetic resonance imaging (MRI) are used to determine tumor response 6-8 weeks after
completion of treatment19. These findings are usually confirmed with positron emission
tomography (PET) imaging of [18F]-Fluorodeoxyglucose (FDG) uptake several weeks later to
avoid high false-positive rate because tracer delivery and uptake can be affected by the postradiation tumor microenvironment20. Although radiographic imaging 6-8 weeks after treatment can
be useful in terms of establishing baseline measurements where future recurrence measurements
can be compared against, it is a very late-stage measurements in terms of radiation response
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evaluation and identification of responding and non-responding patients. Thus, no method can
yet determine radiation response of the individual tumors either during or shortly after
commencement of treatment. Therefore, patients continue to undergo and complete treatment
plan without proper knowledge about treatment efficacy. Information about treatment response
either prior to or shortly after commencement of therapy could potentially help oncologists tailor
treatment plan for individual patients. However, such a knowledge can be gained by having
profound understanding about the underlying physiological and biomolecular events that shape
radioresistant phenotype.
Consequence of radiation therapy on cancer cells
Ionizing radiation produces free radicals in cells either directly in the DNA or indirectly in
other molecules, primarily water (H2O). These radiation-induced free radicals, in the presence of
O2, can generate peroxy radicals (DNA-OO·) capable of breaking chemical bonds and initiating a
series of events which lead to DNA modification, and cell death (damage fixation). In contrast,
lack of O2 leads to the reduction of free radicals in DNA and restoration of the original form of
DNA (DNA-H) leading to cancer cell survival21–23. Landmark studies in clinical head and neck
cancer and soft-tissue sarcoma have found that pre-treatment oxygenation levels were predictive
of treatment response and disease-free survival24–26. This important role of oxygen is the rationale
for fractionated radiation therapy (2 Gy/day for 6–7 weeks), which is believed to re-oxygenate and
radio-sensitize former hypoxic cells and hence, cause cell death via damage fixation27–29.
Hypoxia and its role in radiation resistance
In 1955, Thomlinson and Gray observed uniform distribution of necrotic cells 100-150 μm
away from blood vessels in human tumors and determined that this distance was equivalent to
the diffusion limit of oxygen. They reasoned that these cancer cells had become necrotic because
of the physical distance between them and nearest blood vessels and virtually no oxygen was
available for their respiration. Thus, they postulated that viable cells located between the blood
4

vessels and the necrotic region had a gradual falling gradient in oxygen tension that caused them
to become hypoxic30. The concentration of oxygen dissolved in tissue at the time of radiation has
previously been shown to play an important factor during radiation because hypoxia protects
cancer cells from toxic effects of ionizing radiation23. These landmark findings led to initiation of
multiple clinical trials where patients breathed hyperbaric oxygen while undergoing radiotherapy.
It was rationalized that hyperbaric oxygen breathing can enhance amount of oxygen dissolved in
plasma and hence, increase tumor oxygen tension and therefore eliminate the problem of
hypoxia. However, these clinical trials were not universally successful31 as it later became known
that in addition to chronic hypoxia, other factors including low vascular density and high oxygen
consumption rate can also contribute to tumor hypoxia which cannot be eliminated by greater
oxygen delivery32. For the past few decades, hypoxia has primarily been measured by hypoxiavisualizing markers such as 2-nitroimidazoles. When partial pressure of oxygen < 10 mmHg,
these markers are typically metabolized in biological tissue by undergoing electron reduction and
binding to macromolecules which can then be detected by immunohistochemical antibodies33.
Another technique that enables quantitative determination of hypoxia is oxygen sensing
microelectrodes, which if mounted on the tip of a surgical needle and inserted through the tumor,
can determine partial pressure of oxygen34. Polarographic needles have widely been used in
preclinical and clinical studies and have provided a wealth of knowledge about hypoxia and its
relevance to deficient disease-free survival in HNSCC patients26,35–38. In addition to being
implicated to poor radiation outcome, hypoxia also enhances metastatic potential39. In addition,
hypoxia leads to stabilization of transcription factor hypoxia inducible factor-1 (HIF-1)40. While
HIF-1 expression is inhibited under oxygenated conditions via prolyl hydroxylases (PHDs), its
transcription is significantly upregulated under hypoxic conditions22,41,42. HIF-1 significantly
contributes to tumor aggression and progression by upregulating angiogenic genes, switching to
anerobic metabolism, and protecting cancer cells from oxidative stress43. However, both hypoxia
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markers and pO2 measurements are invasive and not amenable to repeated in vivo
measurements.
In contrast, optical spectroscopy can be used as an alternative to traditional methods of
tumor measurement. Optical spectroscopy is a fiber-based approach using non-ionizing radiation
to non-destructively and non-invasively examine tissue of interest. Their low cost and small
footprint make optical spectroscopy methods an excellent tool for conducting pilot studies in
animal models of cancer and in humans. Since optical measurements using the fiber optic probe
are non-invasive or minimally invasive (depending on the tissue site), the same subject can be
monitored multiple times a day or over weeks to evaluate response to treatment. In addition to its
obvious benefits as a clinical adjunct to existing clinical imaging modalities that cannot be used
every day on patients, optical spectroscopy obviates the need for sacrificing large numbers of
animals at several time points in longitudinal studies to evaluate treatment response.
Optical biopsy of head and neck cancer
Surgical tumor resection is a standard treatment option for early-stage head and neck
cancer patients. However, adequate discrimination between tumor and normal adjacent tissue
remains challenging. Current technologies in clinical environment cannot detect cancer cells and
hence, inspection is limited to visual appearance and palpation of tumor by the trained surgeon.
This has led to poor surgical success because cancerous cell residuals are left out due to
incomplete tumor resection in oral cancer patients44. Thus, several studies have investigated the
potential of optical biopsy for real-time guidance of surgeons during intraoperative cancer
resection.
One such optical biopsy can be collected using in vivo measurements of intrinsic
fluorescence spectroscopy because it has been shown that compared to normal oral tissue, tumor
lesions have lower green and higher red fluorescence45. Based on this premise, Muller et al
compared in vivo intrinsic fluorescence spectra of normal and cancer sites in upper aero-digestive
6

tract of HNSCC patients. They identified biochemical and structural differences between these
sites that were driven by collagen and nicotinamide adenine nucleotide (NAD)46. In a similar study,
Roblyer et al utilized autofluorescence imaging coupled with objective image analysis and were
able to accurately discriminate oral neoplasia from nonneoplastic tissue46. In addition to
autofluorescence spectroscopy, diffuse reflectance spectroscopy (DRS) has also been utilized
towards fulfilling this goal. Beumer et al used DRS in differentiating malignant and non-malignant
head and neck cancer patients and identified significant differences driven by oxygenation of
these two tumor types47. Hu et al used oxygen saturation, total hemoglobin concentration, and
reduced scattering coefficient extracted from DRS measurements for comparing properties of
malignant tumors from contra-lateral normal tissue and observed statistically significant
differences between two sample types48. Several studies have also used Raman spectroscopy
(RS) for such comparisons. On ex vivo tumor samples, Valdez et al identified different indexes of
protein, phenylamine, and lipid between healthy tissue and oropharyngeal carcinoma49. Krishna
et al used in vivo Raman spectra collected from lesions of oral cavity to develop multivariate
statistical algorithm that was able to discriminate normal from abnormal spectra with 94%
sensitivity and specificity50. Barroso et al studied the changes in concentration of water across the
tumor border on tumor specimens freshly excised from oral cavity. They observed Raman spectra
of water had a transition to lower concentrations in healthy surrounding tissue compared with high
concentrations in tumor51. These studies show the premise of optical spectroscopic methods for
guiding surgeons during intraoperative surgery with the goal of accurately differentiating
cancerous lesions from normal surrounding tissue. More simple and inexpensive setups using
fiber-optic microendoscopic systems have also been shown to lead to promising results. Muldoon
et al used such a setup for comparing microendoscopic images of subcutaneous tumor model to
their histopathological assesment52. Using nuclear to cytoplasmic ratio, they presented very
similar results to histopathological gold-standard measurements. In a more recent study, the
same group compared images of oral squamous cell carcinoma specimen acquired by high7

resolution microendoscopy to histopathological classification of neoplastic and non-neoplastic
tissue and found average sensitivity and specificity of 82 and 84% respectively53.
Although these studies present the potential of optical measurements in better diagnosis
of head and neck tumors, translation of these methods to the clinic has been limited due to the
ability of histopathology of tumor biopsies to provide accurate diagnoses. However, patients
undergoing chemoradiation therapy rarely have tissue biopsied before or during therapy.
Therefore, there is a critical and unmet clinical need for technologies to identify treatment
response early during therapy. Given the established ability of optical spectroscopy for evaluating
functional and biomolecular status of tissue and the lack of other standard clinical methods, such
as imaging or biopsy, there is significant potential for successful translation of noninvasive optical
methods to monitor radiation response in HNSCC. In this dissertation, we present two specific
techniques - diffuse reflectance and Raman spectroscopy – to gain a better understanding of
radioresistant phenotype and identify physiological and biomolecular differences among
radiation-sensitive and -resistant tumors that can be exploited in the clinic.
Specific aims
The overall goal of this research is to identify biomarkers that can differentiate late-stage
radiation-responsive and non-responsive patients prior to, or at early days after commencement
of radiation-therapy. However, such an insight requires deeper understanding of underlying
physiological and biomolecular events that shape radioresistant phenotype in a head and neck
patients. This dissertation used two human head and neck cancer models (UM-SCC-22B and
UM-SCC-47) with opposing radiosensitivity in studying physiological and biomolecular differences
between two tumor types. These human-derived cancer cells were used to form murine tumor
xenografts and were treated with small doses of radiation which mimics the employed dose in
treatment of real head and neck cancer patients. First, we used diffuse reflectance spectroscopy
(DRS) in studying physiological changes induced by radiation and whether these changes differed
8

among radiation-resistant and -sensitive tumors. Second, we used Raman spectroscopy (RS) in
studying radiation-induced biomolecular changes in radiation-resistant and -sensitive tumors.
Before utilizing DRS measurements in studying radiation-response, we first sought to
validate the sensitivity of DRS to different levels of oxygenation (Chapter 2). Next, we used DRS
in studying differential radiation-induced reoxygenation kinetics of radiation-resistant and sensitive tumors. Using extracted optical parameters, we trained a logistic regression model which
accurately differentiated -radiation-resistant and -sensitive tumors (Chapter 3). Finally, we used
RS to study innate and radiation-induced biomolecular differences in radiation-resistant and sensitive tumors (Chapter 4). In addition to optical measurements in chapters 3 and 4, we also
investigated the biological pathways that contributed to the observed reoxygenation and
biomolecular changes. Finally, we performed a pilot clinical trial assessing feasibility of diffuse
reflectance measurements in head and neck cancer patients with diseased tonsils. During the
next 3 chapters, this dissertation investigates 3 specific aims outlined as below:
Specific Aim 1: Validate DRS-measured tumor vascular oxygen saturation sO2 using
immunohistochemically determined tumor hypoxic fraction.
Publications:
▪

Dadgar, S., Troncoso, J. R. & Rajaram, N. Optical spectroscopic sensing of tumor hypoxia.
J. Biomed. Opt. 23, 1–10 (2018), chapter 2 of this dissertation.

Background: As mentioned previously, tumor hypoxia at the time of irradiation has been
identified as a hallmark of poor response to radiation as patients with hypoxic tumors survive
significantly shorter compared to patients with well-oxygenated tumors24,25,35. Thus for the past
few decades, hypoxia visualizing markers33,37 and tissue oxygen sensing microelectrodes34–36
have extensively been utilized in measuring tumor hypoxia (or oxygenation) and its association in
radiation-response of preclinical animal models and clinical human patients. However, histological
assessment of hypoxia requires administration of hypoxia probes (e.g. pimonidazole
9

hydrochloride). In addition, microscopic visualization techniques are required for evaluation of
extent of hypoxia which necessitates tumor biopsy or excision. On the other hand, pO 2 sensing
microelectrodes require insertion into tumor thru needles which can distort tumor architecture.
Thus, both methods preclude tumors from longitudinal studies because repeated and repetitive
measurements of tumors is not feasible. In contrast, diffuse reflectance spectroscopy can
measure vascular oxygen saturation in vivo and hence, can be used as a negative indicator of
hypoxia. However, no study has yet investigated the association between optically determinedvascular oxygenation with gold standard methods of hypoxia determination, namely hypoxia
sensing markers.
Objective: To compare optical measurements of tumor vascular oxygenation against
immunohistochemical measures of hypoxia from histological slides collected at three different
depths of tumor including a depth that corresponds to the penetration depth of our optical probe.
Hypothesis: Optically determined vascular oxygen saturation (sO2) and total hemoglobin
concentration (THb) will be negatively correlated with immunohistochemically determined tumor
hypoxia. Specifically, we hypothesize very low values of sO2 and THb to associate with highly
hypoxic tumors and vice versa.
Significance: Non-invasive and in vivo measurement of tumor vascular oxygenation that is a
negative indicator of tumor hypoxia can be an alternative approach for replacing hypoxia
visualizing markers and tissue oxygen sensing microelectrodes. In addition to providing functional
information about tumors, DRS is also capable of characterizing structural changes that occur in
tumor microenvironment as tissue scattering has been shown to be a strong biomarker of cell
necrosis54. This aim is investigated in chapter 2 of this dissertation.
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Specific Aim 2: Investigate radiation-induced short and long-term changes in oxygen
saturation in radiation-resistant and -sensitive head and neck tumor xenografts using
diffuse reflectance spectroscopy.
Publications:
▪

Dadgar, S., Troncoso, J. R., Siegel, E. R., Curry, N. M., Griffin, R. J., Dings, R. P. M. &
Rajaram, N. Spectroscopic investigation of radiation-induced reoxygenation in radiationresistant tumors. Neoplasia 23, 49–57 (2021), chapter 3 of this dissertation.

Background:
Head and neck cancer patients diagnosed at late stage are usually treated with 1.8-2 Gy
of radiation in daily basis for a period of 7 weeks. Dose fractionation is believed to lead to
reoxygenation of former hypoxic cells and hence, increase in cell killing. Thus, phenomenon of
reoxygenation can be used as a biomarker of radiation-response. Several studies have used
diffuse reflectance approach in monitoring radiation-induced reoxygenation kinetic and its
association with radiation response of preclinical animal models of head and neck cancer55,56.
Although these studies established the sensitivity of DRS to radiation-induced reoxygenation and
its association with radiation-response, it remains unclear whether diffuse reflectance
spectroscopy is sensitive to functional changes that are induced by smaller doses of radiation.
Objective: To study short- and long-term reoxygenation kinetics induced by small doses of
radiation and its differences among radiation-sensitive and -resistant tumors. We also sought to
use the observed fold changes in training a logistic regression model to determine if we can
accurately differentiate radiation-resistant and -sensitive tumors. Finally, we investigated the
biological pathways that play important role in causing the observed reoxygenation in radiationresistant and -sensitive tumors.
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Hypothesis: Radiation-sensitive tumors will have a greater rate of reoxygenation in comparison
to radiation-resistant tumors.
Significance: This work provides valuable information about differential functional changes within
radiation-resistant and -sensitive tumor at early time points after treatment with low doses of
radiation which are representative of utilized doses in treatment of head and neck cancer patients.
Our findings illustrate the potential of this technique for clinical translation where treatment
response of patients can be monitored. This aim is investigated in chapter 2 of this dissertation.
Specific Aim 3: Establish early radiation-induced biomolecular alterations in radiationresistant and -sensitive head and neck tumor xenografts using Raman spectroscopy.
Background:
In addition to vascular changes, radiation can also induce biomolecular changes in tumor
microenvironment which can be detected with Raman spectroscopy. Several studies have
associated such biomolecular changes with radiation sensitivity of utilized cells and tumors57–60.
However, such studies of radiation-induced biomolecular changes have been limited to in vitro
cellular studies or excised tumors. No study has yet used in vivo Raman spectroscopy for
monitoring differential biomolecular changes in radiation-resistant and -sensitive tumors.
Objective: To study radiation-induced biomolecular alterations in microenvironment of radiationresistant and -sensitive tumors in early time points after radiation which can be combined with
DRS measurements.
Significance: This work motivates the use of combined diffuse reflectance and Raman
spectroscopy for longitudinal monitoring of tumor oxygenation and biomolecular content and their
evolution in response to radiation in radiation-resistant and -sensitive tumors.
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Chapter 2: Optical spectroscopic sensing of tumor hypoxia
Introduction
Low oxygen tension or hypoxia is caused by the imbalance between oxygen delivery and
consumption1–4. Hypoxia is typically defined at the cellular level as oxygen tension (pO2) < 10
mmHg. Oxygen-sensing Clark microelectrodes have established a wealth of knowledge related
to hypoxia and its role in poor disease-free survival5–7. These electrodes provide a direct measure
of pO2 and hence hypoxia in tissue. To measure oxygen tension in vivo, the electrode is inserted
into tissue to a certain depth and retracted along tracks to provide pO2 measurements at several
points along these tracks. Such measurements of hypoxia have been associated with tumor
aggressiveness, resistance to chemotherapy and radiation therapy4,8–11, and shown to be
predictive of tumor metastases in soft tissue sarcoma12. It has also been reported that local
recurrences have a higher hypoxic fraction (HF) than primary tumors13,14. These studies have
demonstrated that measuring tumor oxygenation either prior to or during therapy could aid in the
selection of appropriate treatment regimens for patients. However, microelectrode-based pO2
measurements are always invasive (requiring tumor penetration), limited to only accessible
organs, can potentially modify the tumor microenvironment, and are not amenable to repeated
measurements in vivo. A combination of pulsed electron paramagnetic resonance imaging and
magnetic resonance imaging has been shown to provide quantitative three-dimensional maps of
tumor pO2 co-registered with anatomical detail in preclinical animal models15. Other than an
intravenous injection of the triarylmethyl radical (TAM) probe used to sense oxygen, this
technology would allow noninvasive and repeated imaging of pO2 in vivo. However, the
instrumentation in its current form presents a challenge to clinical translation.
Other

established methods

to measure

tumor

hypoxia

include

the

use

of

pimonidazole6,7,16,17 and EF518, two widely used markers that provide quantitative measures of
tumor hypoxia. Both pimonidazole and EF5 accumulate by forming adducts with thiol groups

18

present in proteins in hypoxic cells. Pimonidazole accumulates in cells with pO2 < 10 mmHg and
has been used extensively to map hypoxic regions in excised tumors in animal models. EF5 has
been demonstrated in both animal and human studies (using a fluorinated form of EF5) and can
be calibrated to provide information about both location and level of hypoxia19. Since quantification
using these markers requires either tumor excision after administration or the use of radioisotopes
for in vivo labeling, it precludes their use in longitudinal animal and human studies, where tumor
oxygenation could potentially be used as a biomarker of treatment response or local recurrence.
For accessible tumors of the skin and oral cavity, optical fiber-based diffuse reflectance
spectroscopy (DRS) can provide a nondestructive and noninvasive alternative to the
microelectrode for quantitatively evaluating tumor oxygenation. The tissue of interest is
illuminated with visible light from a broadband source (400 to 650 nm) and the reflected light is
used to quantify the underlying scatterers and absorbers, a combination of which is used for
recognition of tissue pathology. Tumor vascular oxygenation (sO2) can be quantified by measuring
the individual contributions of oxygenated (HbO2) and deoxygenated (dHb) hemoglobin within the
blood vessels. Thus, DRS provides an indirect measure of tissue pO2 by quantifying the
“supply”— oxygenation levels in the vasculature using sO2 and perfusion levels using total
hemoglobin concentration (HbO2 + dHb). DRS has previously been used to measure tumor
oxygenation in small animal model studies to determine treatment response. Vishwanath et al
found that longitudinal changes in dHb, as quantified by DRS, after treatment with doxorubicin
were concordant with changes in tumor HF20. Palmer et al demonstrated that DRS-based
measurements of sO2 were more stable compared with microelectrode-based measurements of
pO2; furthermore, the direction of change of sO2 in response to perturbations in the composition
of inhaled air in mice was concordant with pO2 measurements21. This study builds upon these
previous reports to validate DRS measures of sO2 using pimonidazole based quantification of
tumor HF in two human head and neck cancer cell-based xenografts. In addition to evaluating HF
at a depth corresponding to the sampling depth of our probe, we also determined the HF at two
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other depths within excised tissue and compared these measurements to sO2. Our results indicate
that DRS-based measurements of sO2 can provide reliable estimates and thus enable longitudinal
tracking of tumor HF in studies, where tumor hypoxia can be a significant biomarker of treatment
response.
Materials and Methods
Cell culture and tumor xenografts
All studies and protocols were approved by the Institutional Animal Care & Use Committee
(IACUC) of University of Arkansas. Twenty nude mice were housed at the Central Laboratory
Animal Facility (CLAF). Mice were maintained under standard 12-h light/dark cycles with ad
libitum access to food and water. Mice were subcutaneously injected with either UM-SCC-47 (n
= 10) or UM-SCC-22B (n = 10) human head and neck cancer cells. Cells were cultured in a
mixture of Dulbecco’s modified Eagle medium, 10% fetal bovine serum, 1% Penicillin–
Streptomycin, 1% nonessential amino acids, and 1% L-glutamine. Head and neck tumor
xenografts were formed by injecting 1.5 million cells suspended in 1∶1 mixture of Matrigel
(Corning, New York) and saline into the right flank of these animals. When tumor volumes reached
1500 mm3, mice received an intraperitoneal injection of pimonidazole (at a dose of 60 mg/kg). An
hour post injection, the animals were anesthetized by breathing 1.5% isoflurane (mixed with
oxygen) and diffuse reflectance spectra were acquired from each tumor. Immediately after DRS
measurements, the tumors were resected (with skin) and snap-frozen for histology.
Diffuse reflectance spectroscopy
Figure 1(a) presents our DRS setup. This simple and portable system consists of a
halogen lamp (HL-2000, Ocean Optics, Dunedin, Florida) for illumination, a USB spectrometer
(Flame, Ocean Optics) for spectral acquisition, and a bifurcated optical probe for light delivery
and collection. DRS spectra were acquired in the wavelength range of 475 to 600 nm. The
common end of the probe is illustrated in Figure 1(b) and consists of four illumination fibers and
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five detector fibers located at a source–detector separation distance (SDSD) of 2.25 mm. Based
on previously described methods, we determined the sampling depth of this SDSD to be ∼1.8
mm22. Reflected light spectra were collected using this system with an integration time of 100 ms.
Spectral acquisition was simplified with the use of a foot pedal controlled by custom LabVIEW
(National Instruments, Austin, Texas) software. With the exception of three tumors on which
multiple spectra were recorded, only one spectrum was measured from each tumor. For tumors
with multiple spectra, averaged optical properties were used to represent that tumor. Spectra
acquired from tissues were background-subtracted to correct for dark current and ambient light.
To calibrate for light throughput, the background-subtracted reflected light intensity from tissue
was divided by background-subtracted reflected light intensity from an 80% reflectance standard
(SRS-80-010; Labsphere, North Sutton, New Hampshire).
Quantification of tissue optical properties
We used a lookup table (LUT)-based model to fit the acquired DRS spectra and extract
wavelength-dependent absorption and scattering properties from tissue. The LUT-based model
has been described in detail previously23 and validated for a range of SDSD22. Briefly, the LUT is
generated from reflectance spectra acquired from a matrix of tissue-simulating phantoms of
known absorption (𝜇𝑎 ) and scattering (𝜇𝑠 ′) coefficients. These phantoms contained India ink (Salis
International Inc., Golden, Colorado) and polystyrene microspheres beads (diameter = 1 μm;
Polysciences, Warrington, Pennsylvania) of known concentrations dissolved in water to create a
range of absorption and scattering coefficients, respectively. The LUT corresponding to the SDSD
used in this study was validated using tissue-simulating phantoms and found to have errors of
9.5% and 1.5%, respectively, for quantifying 𝜇𝑎 and 𝜇𝑠 ′, respectively. To fit the model to the data,
we constrained scattering to a power law dependence on wavelength and represented it by the
𝜆 −𝐵

equation: 𝜇𝑠′ (𝜆) = 𝜇𝑠′ (𝜆0 ). (𝜆 )
0

, where 𝜆0 = 630 nm. The absorption coefficient is computed as

a linear sum of absorbers based on Beer–Lambert’s law. Assuming the principal absorbers to be
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HbO2, dHb, and mouse skin, the absorption coefficient is given by : 𝜇𝑎 (𝜆) = [𝐻𝑏][𝛼𝜎𝐻𝑏𝑂2 (𝜆) +
(1 − 𝛼)𝜎𝐻𝑏 (𝜆)] + [𝐶]𝑠𝑘𝑖𝑛(𝜆), where α is the vascular oxygenation and σ is the extinction
coefficient of hemoglobin (oxygenated or deoxygenated). We have previously shown that the
effects of pigment packaging, which describes the inhomogeneous distribution of hemoglobin
within tissue, are minimal at wavelengths beyond 500 nm24. Therefore, we did not include a
correction factor to account for pigment packaging.
Immunohistochemistry
All harvested tumors were sectioned using a Cryostat (CM 1860; Leica, Inc., Nussloch,
Germany) to slices of 10 μm. Care was taken to slice the frozen tumors starting from the skin
side, where the DRS measurements were initiated. Multiple slices were acquired from each tumor
at depths corresponding to 0.8, 1.8, and 2.8 mm, with separate, sequential slices utilized for
immunofluorescence and histology. All the collected samples were immunestained with a direct
labeling protocol. First, the slides were hydrated in phosphate-buffered saline (PBS) and
permeabilized with 0.1% Triton-X. Next, the slides were incubated with blocking solution (95%
PBS, 4% goat serum, and 1% sodium azide) in room temperature for an hour and stained with
mouse monoclonal antibody conjugated to Dylight™ 549 fluorophore (Hypoxyprobe Red549 kit;
HPI, Inc., Burlington, Massachusetts) for an hour in a dark room. Finally, slides were rinsed with
PBS, covered with fluoromount, and coverslipped with nail polish. Slides were dried for 24 h prior
to imaging. All images were acquired using a 4× objective on a Nikon fluorescence microscope
with same settings (binning, exposure time, and gain).
Quantification of hypoxic fraction and image analysis algorithm
Pimonidazole accumulates in tissue, where the intracellular oxygen level drops below 10
mmHg25. We analyzed all of the acquired immunofluorescence images using MATLAB
(Mathworks; Natick, Massachusetts). At each depth within the tumor—0.8, 1.8, and 2.8 mm
[Figure 2(a)]—immunofluorescence and histology (H&E-stained) images were acquired from
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multiple fields of view from each tumor slice. For representative purposes alone, a fully stitched
image of pimonidazole immunofluorescence is presented in Figure 2(b) along with its
corresponding H&E image from an adjacent tumor slice. Each tumor slice consisted of an average
of 15 fields of view (1.5 mm × 1.1 mm). We converted each individual image to its gray-scaled
and normalized version and calculated a threshold using Otsu’s method to segment out the
pimonidazole- positive pixels26. Next, we averaged all thresholds to compute a global threshold.
This global threshold was used to segment all of the images, and HF of each image was quantified
as the ratio of hypoxic (segmented) pixels to the total number of tissue pixels. Figure 2(c) presents
a flowchart of the image processing algorithm employed for this analysis. The average HF
corresponding to each depth within a tumor is reported here.
Results and Discussion
Figure 3(a) presents DRS spectra and their corresponding LUT fits (red lines) for two
different tumors that were excised at similar tumor volumes. Quantification of optical properties
using the LUT fits identified different values of sO2 for each tumor. This is evident in the
wavelength-dependent absorption coefficients for each tumor, which demonstrate the classic
double peaks of HbO2 (542 and 577 nm) for the tumor with recovered sO2 of 58%. On the other
hand, the 𝜇𝑎 spectrum for the tumor with sO2 of 15% indicates poor oxygenation with a single
peak corresponding to dHb [Figure 3(b)]. IHC images of HF corresponding to both tumors
illustrate that the tumor with higher sO2 has a lower percentage of hypoxic tissue compared with
the low-sO2 tumor [Figure 3(c)].
We determined the association between the HF and the scattering and absorption
properties of the UM-SCC-22B and UM-SCC-47 tumors. We found a statistically significant
negative correlation (r = −0.50; p = 0.02) between the HF and sO2 [Figure 4(a)]. We also observed
similar statistically significant correlations of the HF with THb [Figure 4(b); r = −0.45; p = 0.04] and
HbO2 [Figure 4(c); r = −0.59; p = 0.006]. Taken together, these results indicate that measurements
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of vascular sO2 and THb can provide reliable estimates of the hypoxic state of tissue. Specifically,
very low values of sO2 and THb can point to highly hypoxic and poorly perfused tumor.
In addition to evaluating hemoglobin-based parameters, we determined the relationship
between HF and the mean reduced scattering coefficient [Figure 4(d)]. We found a statistically
significant positive correlation between the two parameters (r = 0.60; p = 0.005). Since all our
tumors were excised at similar tumor volumes, this correlation is unlikely due to tumor volume. A
previous study using optical spectroscopy by Vishwanath et al found a highly significant positive
correlation between mean reduced scattering coefficient and tumor necrotic fraction20. Although
we do not completely understand the relationship between HF and scattering in our study, it is
possible that the highly hypoxic tumors also contained larger necrotic areas—the cellular and
structural changes associated with tumor necrosis could potentially contribute to the increased
scattering seen here27,28. Our future studies include plans to transiently modify tumor hypoxia
levels6 and measure the association between HF and tissue scattering and absorption. These
studies could potentially shed further light on the basis for these interactions.
We also investigated the HF as a function of depth within each tumor. HF was calculated
at additional depths of 0.8 and 2.8 mm from the surface of the tumor. For each tumor, the foldchange in HF at 1.8 and 2.8 mm was calculated with respect to the HF at 0.8 mm. Although we
observed a trend toward increasing HF with depth, this was not statistically significant (Figure 5).
These results are similar to a recent study using multispectral optoacoustic tomography on
prostate cancer xenografts that found a well-oxygenated rim and a large decrease in oxygenation
toward the tumor core29. Furthermore, we did not find statistically significant correlations between
optical properties and HFs at depths of 0.8 and 2.8 mm (data not shown). Although tumor
xenografts are typically considered to be homogeneous, it is interesting to note a lack of
correlation at depths that do not lie within the range of sampling depths of the probe.
In summary, we have demonstrated that the vascular oxygenation and total hemoglobin
concentration measured using DRS are concordant with measurements of HF and can provide
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reliable indirect measures of tumor oxygenation. Monitoring changes in tumor oxygenation during
therapy—radiation or chemo—can provide clinicians with a complementary aid to identify
treatment response and provide opportunities to investigate hitherto unknown reoxygenation
kinetics in preclinical animal models in response to clinically relevant treatment regimens.
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Tables and figures

Figure 1. (a) Experimental DRS setup and (b) bifurcated fiber optic probe illustrating the common
tissue end, the source end that is connected to the light source, and the detector end that is
connected to the USB spectrometer.
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Figure 2. (a) Schematic of optical probe placed on tissue indicating the three depths at which
tumor slices were extracted for immunohistochemistry. (b) Stitched H&E and pimonidazole
immunofluorescence images of a tumor slice from a depth of 1.8 mm. Scale bar corresponds to
1.8 mm. (c) Flowchart describing the image analysis to calculate HF. Scale bar in these images
corresponds to 600 μm.
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Figure 3. (a) Representative in vivo DRS spectra and their LUT fits from UM-SCC-22B tumors
with different levels of sO2. (b) Corresponding wavelength-dependent absorption coefficients
determined from LUT fits to the spectra. (c) Processed pimonidazole immunofluorescence images
from the same tumors. The calculated HF and vascular oxygenation are shown for each image.
Scale bar corresponds to 600 μm.
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Figure 4. Scatter plots representing the relationship between HF measured at a depth of 1.8 mm
and DRS-based measures of (a) sO2, (b) THb, (c) HbO2, and (d) mean 𝜇𝑠 ′ from UM-SCC-22B
(red stars) and UM-SCC-47 (blue asterisks). Black solid line indicates the regression line.
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Figure 5. Fold-change in tumor hypoxia levels with depth relative to the HF measured at 0.8 mm.
Error bars represent standard deviation of the mean.
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Chapter 3: Spectroscopic investigation of radiation-induced reoxygenation in radiationresistant tumors
Introduction
The majority of patients diagnosed with head and neck squamous cell carcinoma
(HNSCC) present with locally advanced disease (Stage III or IV)1 and are treated with a
combination of surgery, radiation, and chemotherapy2. The treatment regimen can last several
weeks and typically takes the form of daily radiation therapy - 2 Gy/day; 5 days/week for 7 weeks
– and weekly chemotherapy sessions. The delivery of radiation therapy in multiple fractions is
hypothesized to cause cell death of oxygenated cells and leads to reoxygenation and
radiosensitization of previously hypoxic cells3–5. Fractionated radiation therapy is believed to
overcome the challenge of hypoxic tumors, which have been shown to be associated with poor
long-term outcome6–9. Studies in patients and animal models using oxygen-sensing
microelectrodes have offered evidence that an increase in tumor oxygenation or reoxygenation
between dose fractions is associated with positive treatment response10,11. Despite providing
absolute measures of oxygenation in tissue, these microelectrodes could disrupt the
microenvironment when inserted into the tumor and are therefore not amenable to repeated
measurements.
In contrast to microelectrodes, diffuse reflectance spectroscopy is an optical fiber-based
technique that can non-invasively quantify hemoglobin oxygen saturation within a sampled tissue
volume. DRS is sensitive to light absorption by hemoglobin, the primary oxygen carrier in blood,
and can determine the concentrations of oxygenated and deoxygenated hemoglobin present and
hence allow calculation of hemoglobin oxygen saturation12,13. Measurements of hemoglobin
oxygen saturation from tumors with DRS have been shown to be concordant with simultaneous
pO2 measurements using oxygen-sensing microelectrodes14,15. In addition, we have found a
significant negative correlation between vascular oxygenation and immunohistochemical
assessment of tumor hypoxic fraction16. Leveraging the noninvasive capabilities of DRS and its
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sensitivity to tumor hemoglobin oxygen saturation, Hu et al found that early reoxygenation during
the treatment regimen was associated with treatment failure whereas late reoxygenation about
10 days after treatment was associated with local control in head and neck tumor xenografts 17.
These studies utilized a hypofractionated dosing schedule of 7.5-13.5 Gy/day for 5 consecutive
days. Interestingly, previous work from our lab has also uncovered radiation-induced
reoxygenation in radiation-resistant lung tumor xenografts in the first 24-48 hours after radiation.
These studies were conducted in a matched model of radiation resistance treated with
conventional fractionation of four 2 Gy doses over two consecutive weeks18. However, this work
did not explore the mechanism of reoxygenation in the treatment-resistant tumors or relate
reoxygenation to treatment outcome.
The primary goal of the current study was to determine radiation-induced changes in tumor
oxygenation in head and neck tumor xenografts and investigate the association of this
reoxygenation with tumor local control or recurrence. We used two previously characterized
patient-derived HNSCC cell lines - UM-SCC-22B and UM-SCC-47 – to represent radiation
sensitivity and resistance, respectively19,20, and treated tumor xenografts with four 2 Gy fractions
over 2 consecutive weeks (total dose of 8 Gy). We acquired optical spectra and quantified tumor
oxygenation every day for 14 days, including immediately before and an hour after radiation on
treatment days. Our results suggest that while reoxygenation patterns can be observed in both
radiation-resistant and -sensitive tumors, the kinetics and source of this reoxygenation can be
very different, depending on the radiation sensitivity. Given the importance of oxygen supply and
consumption within a tumor and their roles in modulating response to radiation, these results shed
light on the importance of longitudinal, real-time measurements of tumor oxygenation during
radiation therapy to differentiate radiation responders from non-responders and hence improve
response rates.
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Materials and Methods
Cell culture
Cell culture conditions have been reported in detail in chapter 2. Oxygen consumption rate
(OCR) of UM-SCC-22B and UM-SCC-47 cells were determined using a Seahorse metabolic flux
assay as described previously21. Head and neck tumor xenografts were formed by injecting 1.5
million cells suspended in 1∶1 mixture of Matrigel (Corning, New York) and saline into the right
(treated group) or both (control group) flanks of nude mice (see tumor distribution in Table 1).
Tumor xenografts and fractionated radiation treatment
Animals in the treated (XT) groups underwent radiation treatment with four doses of 2 Gy
over two consecutive weeks (8 Gy in total)20 using an X-rad 320 biological cabinet (Precision XRay, North Branford, CT) (see treatment schedule in Figure 1A), while animals in the NT groups
served as controls. Animals were placed in the center of a 20 x 20 cm X-ray radiation field. During
radiation treatment, mice were kept under anesthesia using a mixture of isoflurane (1.5% v/v) and
oxygen while the entire animal body was covered under lead blocks except the tumor. Greening
et al have shown this combination and dose to closely mimic no anesthesia conditions22. Mice
were monitored daily, and tumors were excised if: 1) tumor volume reached 1500 mm 3 2) tumor
necrosis was observed 3) other health related issues occurred. A subset of mice from each of the
4 groups were euthanized and tumors were excised at baseline, 24, and 48 hours after a single
2 Gy dose of radiation (see Table 2).
Diffuse reflectance spectroscopy
Our portable spectroscopic system consists of a tungsten halogen lamp (HL-2000, Ocean
Optics, Dunedin, Florida) as light source, a USB fiber optic spectrometer (Flame, Ocean Optics)
for spectral light acquisition, and a bifurcated optical probe (dia.= 200 µm, NA=0.22; FiberTech
Optica, Kitchener, ON, Canada) for light delivery and collection. The probe tip was used for light
delivery and collection and is equipped with four illumination and five detector fibers located at a
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source-detector separation distance (SDSD) of 2.25 mm with a sampling depth of approximately
1.8 mm13. We used a foot pedal controlled with custom LabVIEW software (National Instruments,
Austin, Texas) for data acquisition. About 2-5 spectra in the wavelength range of 475 to 600 nm
were collected and averaged optical properties were used to represent that tumor in temporal
analysis. Because the surface area of our probe (32 mm2) is always smaller than the surface area
of typical tumor under investigation (average ~ 200 mm2), we were able to collect multiple spectra
from various parts of the tumor. Prior to any optical measurement from animals, reflected light
intensity from an 80% reflectance standard (SRS-80-010; Labsphere, North Sutton, New
Hampshire) was acquired to calibrate for daily variations in light throughput. Optical spectra from
each tumor were recorded daily for a period of 14 days (see optical measurements schedule in
Figure 1A) while animals were under anesthesia (1.5% v/v isoflurane mixed with 100% oxygen).
Analysis of acquired optical spectra was performed using an experimental model. See chapter 2
for details.
Logistic regression and leave-one-out cross-validation
To construct an artificial intelligence-based classification algorithm, we employed a logistic
regression (LR) model because of its simplicity. Five extracted optical properties from each tumor
normalized to its pre-treatment value were used as input parameters while the model output
discriminates two classes (local-control: 0, treatment-failure: 1). In order to train our LR model,
we used the spectra from 27 treatment-failure and 16 local-control tumors. We labeled our tumors
to be treatment-failure if two weeks after initiation of therapy, the volume had increased ≥ 25% of
the initial volume of 200 mm3. Weights of the LR model were fine-tuned using gradient decent
optimization algorithm with a learning rate of 0.0001. The training weights were iteratively adjusted
for 50 epochs. Model accuracy was assessed using a leave-one-out cross-validation algorithm.
All optical properties of individual tumors and their corresponding binary label were sequentially
excluded, and the remaining data set were used to train the model and the accuracy of the model
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was evaluated on the left-out tumor. Logistic regression analysis was conducted by scripts written
in MATLAB (Mathworks, Natick, Massachusetts).
Immunohistochemistry
An hour prior to euthanasia, mice were injected (i.p.) with Pimonidazole (60 mg/kg –
Hypoxyprobe, Burlington, MA). After tumor resection and euthanasia, the flash-frozen tumors
were sliced into sections of 10 μm using a cryostat (CM 1860; Lecia, Inc., Nussloch, Germany).
We followed a direct labeling protocol in immunostaining of harvested samples23: After
acclimatization to room temperature, slides were hydrated in PBS and a hydrophobic barrier was
formed around each tissue section using a pap pen (Vector Laboratories, Burlingame, CA). Slides
were fixed with 4% PFA, permeabilized using 0.5% Triton-X 100, and non-specific binding was
blocked at room temperature using an in-house blocking solution (95% PBS + 4% goat serum +
1% sodium azide) for an hour. Slides were then stained with mouse monoclonal antibody
conjugated to DylightTM 549 fluorophore (Hypoxyprobe Red 549 kit; HPI, Inc, Burlington, MA).
Serial slides were also incubated with primary HIF-1α rabbit (NB100449 – NOVUS Biologicals,
Littleton, CO) and VEGF-R2 rabbit (9698S – Cell Signaling Dancers, MA) antibodies for 3 hours
at room temperature. The slides were next tagged with Alexa Fluor 488 goat anti-Rabbit (A-11008,
Thermo Fisher Scientific, Waltham, MA; for HIF-1α) and (4412S-Cell Signaling; for VEGF-R2).
The entire tumor section on each slide was imaged using a confocal microscope (Fluoview FV10i,
Olympus) using a 10X objective (UPLSAPO10X, NA = 0.4, Olympus). Images acquired from
individual regions of interest (ROI) were stitched using the microscope software. Stitched images
were binarized using a fixed threshold to separate pixels containing true signal from the
background. This fixed threshold was identified from representative histograms where the signal
of non-specific background differed from the true signal. Four tumor sections were treated without
Pimonidazole-specific,

HIF-1α-specific,

and VEGF-R2-specific

antibodies

to

determine

endogenous tissue autofluorescence, which was found to be negligible. Two tumor tissue sections
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were also incubated with secondary AF488 antibody without HIF-1α and VEGF-R2 specific
antibodies to determine the presence of any non-specific binding tissue section, which was found
to be absent. Finally, percentage of Pimonidazole positive, HIF-1α positive, and VEGF-R2 positive
pixels within each tissue section was calculated by dividing segmented pixels by the total number
of tumor tissue pixels.
It is worth mentioning that HIF-1α from Santa Cruz biotechnology (13515) had strong nonspecific binding and did NOT provide reliable results. This was determined by treating 3
specimens on the same slide with primary and secondary, secondary alone, and no antibodies
which helped us in determining the presence non-specific binding and tissue autofluorescence.
Statistical analysis
Overall survival in each mouse was measured as the length of time in days from when the
mouse’s tumor reached 200 mm3 to when the mouse was euthanized for excessive tumor size
(defined as a tumor volume of ≥1500 mm3). Since the animals from control groups were inoculated
with tumors on both flanks, overall survival in a control-group mouse was marked as starting on
the day when its first tumor reached the volume of 200 mm3. Any animal that died for a reason
other than excessive tumor size had its overall survival right-censored on the day of its death.
The differences in overall survival between groups were compared statistically using the 2-sided
log-rank test with p<0.05 significance level, while the survival benefit with radiation therapy was
quantified as the inverse of the Cox-regression hazard ratio comparing treated to control animals.
Prior to statistical analysis, the raw volume data were logarithmically transformed with the
aim of minimizing the correlation of group means with group standard errors. The transformed
data then were analyzed using repeated-measures analysis of variance (ANOVA) using the
MIXED procedure in SAS v9.4 (The SAS Institute, Cary, NC, USA). The analysis model for logvolumes employed an ante-dependence structure to model the covariance over time among the
longitudinally collected data and utilized the Kenward-Roger method to determine test-statistic
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degrees of freedom. Within each cell line, the right flanks from control-group mice were compared
to the right flanks from XT-group mice. Within each combination of cell line and treatment, mean
log-volumes on subsequent days of growth were compared to their Day 1 value. All comparisons
employed an unadjusted p<0.05 significance level (2-sided) despite the multiple comparisons, in
order not to inflate Type II (false-negative) error.
Raw optical properties from day 1 through 14 from right flanks were normalized by
treatment group to the group mean of the value it had on day 1. This way, values on day 1 have
mean of 1 but individual values different from 1 (i.e. they show variability), and thus can be
included in the analysis. The normalized data were then subjected as before to repeatedmeasures ANOVA using the MIXED procedure in SAS v9.4 software. For each normalized optical
property, the analysis model employed an unstructured autocovariance matrix to model the
covariance between different measurements performed on the same tumor over time and utilized
the Kenward-Roger method to determine test-statistic degrees of freedom. All comparisons
between treatment groups or time points were conducted as previously described and employed
an unadjusted p<0.05 significance level (2-sided) despite the multiple comparisons, in order not
to inflate Type II error.
We used the Wilcoxon rank sum test for statistical analysis of immunohistochemical data.
All tests employed a 2-sided p<0.05 significance level.
Results
Figures 1B-C present the Kaplan-Meier curves for the UM-SCC-22B and UM-SCC-47
tumors, respectively. Animals growing UM-SCC-22B tumors that were irradiated (XT) survived
significantly longer compared with non-irradiated controls (NT), with a mean survival of 56.4 vs.
21.9 days (log-rank p<0.0001); the associated survival benefit with radiation treatment was 44.7
(indicating 44.7-fold higher survival for irradiated tumors) with a 95% confidence interval [CI] of
9.34–214. Although the heavy censoring in irradiated UM-SCC-47 tumors (Figure 1C) prevented
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us from seeing appreciable delay in mean survival compared with non-irradiated controls (mean
survivals of 28.5 vs. 25.5 days), we still observed a significant difference in survival of the NT and
XT groups (log-rank p=0.0052) with an associated survival benefit of 5.51 (95% CI: 1.48-20.5) for
XT groups. Figure 1D-E presents measurements of tumor volume during and after radiation
therapy of the UM-SCC-22B and UM-SCC-47 tumors. As early as day 2, fractionated radiation
therapy resulted in significant differences between the volume of NT and XT groups of UM-SCC22B tumors (p < 0.0001; illustrated in Figure 1D by black asterisk for day 2 and black forward
arrow for following days). In contrast, there were no significant differences between the UM-SCC47-NT and -XT groups, and mean tumor volumes in both groups were nearly identical for the first
7 days (Figure 1E). Importantly, tumor volumes in the UM-SCC-22B-XT group were significantly
higher than baseline only after Day 21 (p = 0.001); for all other groups, the increase in tumor
volume was significant beginning Day 2.
To determine radiation-induced changes in tumor oxygenation, we quantified the optical
properties from the measured DRS spectra (Figure 2) and computed the fold-change in the
measured parameters over time with respect to their pre-radiation baseline measures. Figure 3AD illustrates the fold-change in hemoglobin oxygen saturation (sO2) and total hemoglobin
concentration (cHb). Radiation therapy did not cause significant changes in sO2 or cHb in the UMSCC-22B tumors (Figure 3A&C). There was a significant increase in sO2 in the irradiated UMSCC-47 tumors compared with pre-radiation baseline sO2 (p < 0.05) and this significant
reoxygenation trend was evident on several days over the 14-day period when these tumors were
monitored (Figure 3B). The irradiated UM-SCC-47 tumors also showed a significant decrease in
cHb compared with pre-radiation baseline (Days 6, 7, 10, 13 and 14) and the non-irradiated group
(Days 6, 8, and 14) (p < 0.05; Figure 3D). Analysis of oxygenated (HbO2) and deoxygenated
hemoglobin (dHb) concentrations showed that the temporal decay in cHb and the increase in sO2
in the UM-SCC-47 tumors could be attributed almost entirely to a decrease in dHb while there
was no significant change in HbO2 (Figure 3E-H). Finally, we also extracted the mean reduced
40

scattering coefficient (µs’) of our tumors in all groups. We observed temporally significant increase
in µs’ among both NT and XT groups of UM-SCC-22B tumors after second dose of radiation (red
& blue pounds – Figure 3I) while no significant changes were reported for UM-SCC-47 tumors
(Figure 3J).
While there was an overall increase in tumor oxygenation in the UM-SCC-47 tumors over
the 14-day period, we found that reoxygenation trend was cyclical, consisting of several rapid
increases followed by decreases in tumor oxygenation. To investigate this cyclical nature of
reoxygenation, we studied the short-term effects of radiation therapy on tumor sO2 over the 48
hours following each dose of radiation. Figure 4 presents data from 1, 24, and 48 hours posttherapy for each of the 4 doses. In response to each dose of radiation, there was an increase in
sO2 in the UM-SCC-22B and UM-SCC-47 tumors 1 hour after radiation; this reoxygenation was
statistically significant after the first, third, and fourth doses in the UM-SCC-22B (p<0.01). After
each dose, this increase in sO2 was followed by a decrease to baseline levels over the next 48
hours. Similarly, UM-SCC-47 tumors displayed an increase in mean sO2 immediately after
radiation that was followed by a large decrease at the 24-hour time point. However, at the 48hour time point, the mean sO2 was greater than the pre-radiation baseline for that dose (Figure
4B). Within these cell lines, the radiation-induced changes in sO2 appear to be driven by different
factors in the UM-SCC-22B and the UM-SCC-47 tumors. The large increase in sO2 in the UMSCC-22B tumors immediately after radiation is due to a statistically significant increase in HbO 2.
On the other hand, the increase in sO2 in the UM-SCC-47 tumors is due to a decrease in dHb
over time (Figure 4C-F).
Reoxygenation following radiation has been shown to upregulate HIF-1α in tumors24.
Therefore, we examined the extent of tumor hypoxia and HIF-1α expression in the UM-SCC-22B
and UM-SCC-47 tumors over the first 48 hours following radiation therapy (Table 2, Figure 5,
Figure 6A). Figure 6B-D presents the results of immunohistochemical assessment from tumor
sections collected at baseline, 24h, and 48h after a single 2 Gy dose of radiation in the NT and
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XT groups. Our results indicate that in comparison to UM-SCC-22B tumors, UM-SCC-47 tumors
have slightly higher hypoxic fraction and a significantly higher HIF-1α expression at baseline (p=
0.02). Radiation therapy had different effects on the hypoxic fraction and HIF-1 expression in the
two tumor groups. We observed an increase in hypoxic fraction in the UM-SCC-22B tumors 24and 48-hours (p=0.03) following radiation therapy and a trend towards decreasing hypoxic fraction
in the UM-SCC-47 tumors. While we found no changes in HIF-1α expression in the UM-SCC-22B
tumors following radiation, there was a trend towards a decrease in HIF-1α expression in the UMSCC-47 tumors at the 48-hour time point.
Tumor hypoxia and increased HIF-1 expression has been known to promote angiogenesis
via increased expression of vascular endothelial growth factor (VEGF)25,26. Thus, we investigated
the presence and extend of VEGF-R2 in our tumor sections. Figure 8A presents representative
images of immunostaining of VEGF-R2 at baseline and 1 hour after radiation in radiation-sensitive
and -resistant tumors. Quantitative assessment of histological slides identified significant increase
in expression of VEGF-R2 1 hour after radiation in UM-SCC-22B radiation-sensitive tumors.
However, UM-SCC-22B responsive tumors had relatively lower levels of VEGF-R2 both at
baseline and in 1, 24, and 48 hours after radiation.
In addition to using optical spectroscopy in understanding differential reoxygenation
patterns among radiation-resistant and -sensitive tumors, we also sought to investigate whether
these measurements can provide a diagnostic scheme in classifying local-control and treatment
failure tumors. Although UM-SCC-22B tumors are sensitive to radiation as demonstrated by this
study and others20, 8 out of 24 UM-SCC-22B tumor bearing animals were treatment-failures.
Using logistic regression algorithm, we conducted leave-one-out cross-validation based on the
changes in optical properties of days 2 through 14 with respect to day 1. The leave-one-out crossvalidated area under the curve (AUC) computed from a logistic regression model based on
changes in optical properties in 4 representative days are 0.62 (day 2), 0.58 (day 5), 0.59 (day 9),
and 0.59 (day 11). The corresponding daily receiver operating characteristic (ROC) curves are
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shown in Figure 9 A-D. We finally confirmed the robustness of our LR analysis by randomly
assigning class labels to same dataset and observed that the overall accuracy of the model
decreased to the accuracy of random classifier (0.49, 0.44, 0.47, and 0.49 in days 2, 5, 9, and 11,
respectively). Taken together, the results of the LR and leave-one-out classifier model
demonstrate the capability of changes in optical properties in determining radiation response.
Discussion
Reoxygenation following radiation therapy has long been postulated to be an important
mechanism in the radiosensitization of previously hypoxic cells within a tumor and has been
shown to be an indicator of tumor response to radiotherapy. However, there is also evidence that
reoxygenation following radiation is a double-edged sword because it can lead to radiation
resistance. Temporal investigations of tumor reoxygenation are challenging because the
technologies utilized are either invasive (oxygen-sensing microelectrodes or tissue removal) or
expensive (magnetic resonance imaging, positron emission tomography), and are not amenable
to repeated measurements. Diffuse reflectance spectroscopy (DRS) has been used in animal
studies to identify differences between partial and complete responders based on differences in
sO2 in response to high doses of radiation/fraction (7-39 Gy)17,27. Our long-term clinical goal is to
investigate whether using DRS to measure tumor functional changes in HNSCC patients, who
are typically treated with dose fractions of 2 Gy, can be validated as a predictor of treatment
response. Here, we used DRS to monitor the reoxygenation kinetics of HNSCC tumors with
known radiation sensitivity.
Previous work has shown that the UM-SCC-22B tumors are sensitive to radiation therapy
while the UM-SCC-47 tumors do not respond to therapy when treated with four doses of 2 Gy
over two consecutive weeks20. While the outcomes for both cell lines in our study were largely
consistent with this report, there was a significant difference in tumor growth delay in the UMSCC-22B beginning the day after treatment, while the report by Stein et al found significant
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differences only beginning Day 15. In fact, the mean tumor volume in the irradiated tumors
remained unchanged during and up to 1 week after four 2 Gy fractions were administered over 2
weeks. This corresponded to no significant change in tumor hemoglobin oxygen saturation over
the 14 days of treatment monitoring, indicating that therapy had likely arrested cell proliferation
within these tumors. It is important to note that while there were no long-term changes in sO2 or
cHb in the UM-SCC-22B tumors, there were immediate radiation-induced increases in
oxygenation 1-hour post-treatment (Fig. 3) that are largely consistent with previous studies that
utilize DRS to monitor radiation response18,27. Moreover, the control UM-SCC-22B and UM-SCC47 tumor that grow at the same rate as the irradiated UM-SCC-47 tumors also show nearly no
change in oxygenation with respect to baseline. A lack of reoxygenation has been observed in
head and neck cancer patients about two weeks into daily treatment with fractionated radiation
therapy (2 Gy/day)8. Stadler et al reported a statistically significant reduction in pO2 and increase
in hypoxic fraction in locally advanced HNSCC patients who were evaluated 3 weeks after
commencing fractionated therapy at 2Gy/day. This decrease in pO2 was observed in both
complete and partial responders28. They attributed the observed reduction in pO2 to reduction of
blood flow in response to radiation. Conversely, increases in tumor oxygenation have also been
reported in response to 5 doses of 2 Gy in head and neck tumor xenografts although the observed
changes did not correlate with response/failure11.
In contrast to the UM-SCC-22B tumors, we noted a significant increase in sO2 in the UMSCC-47 tumors which are relatively non-responsive to radiation. Other studies using DRS to
investigate radiation-induced increase in oxygenation have attributed these changes to increased
perfusion17,27, which typically manifests as an increase in oxygenated hemoglobin (HbO 2). When
we investigated the changes in hemoglobin concentration, we found that the increased sO2 was
not due to increased HbO2 but rather due to a decrease in deoxygenated hemoglobin
concentration (dHb). By Day 14, the dHb concentration in the UM-SCC-47 tumors had declined
to about 79% of its baseline value while HbO2 remained unchanged compared with pre-radiation
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baseline. A reduction in deoxygenated hemoglobin concentration in the vasculature points to a
decrease in oxygen consumption in the surrounding tumor tissue. This would be congruent with
a number of studies in the literature, such as one where SCCVII murine tumors treated with 10
Gy of radiation exhibited a reduction in hypoxia found to be caused by a combination of decreased
oxygen consumption and increased perfusion29. In HNSCC patients treated with daily fractions of
2 Gy (total of 70 Gy), Lyng and colleagues have shown changes in oxygenation, determined by
polarographic needles, to coincide with changes in biopsy-determined cell density30. Lack of
simultaneous changes in vascular density led them to conclude that the observed changes in
hypoxia were caused by changes in OCR rather than changes in delivery. Notably, in patients
with advanced HNSCC treated with hyper-fractionated radiation therapy, Dietz et al found that
complete or partial responders show minimal change in reoxygenation in comparison to a strong
reoxygenation among non-responding patients31.
Although reoxygenation has been considered to lead to cell kill, reoxygenation following
radiation can also lead to the generation of reactive oxygen species (ROS) following hypoxiareoxygenation injury and hence, the stabilization of HIF-132. This is supported by an elegant study
by Moeller et al where mice with 4T1 mammary adenocarcinoma tumors showed HIF-1 activation
following radiation that coincided with reoxygenation24. We have previously shown that radiationresistant human lung cancer cells have lower oxygen-consumption rate (OCR) and higher HIF-1
content both at baseline and 24 hours after a single dose of 2 Gy compared with their radiationsensitive counterparts21. In addition, we have also shown that increased HIF-1 content leads to
increased glucose uptake and hence an increased in reduced glutathione which led to a reduction
in mitochondrial ROS production. Treatment with a HIF-1 inhibitor led to a decrease in HIF-1,
glucose uptake and reduced glutathione and led to increased cell death in the radiation-resistant
cells in comparison with the radiation-sensitive cells33. Our observation of a decrease in dHb, a
corresponding increase in sO2, coupled with greater HIF-1α expression both prior to and after
radiation therapy in the UM-SCC-47 tumors compared with the UM-SCC-22B tumors strongly
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suggests that these changes are due to a decrease in oxygen consumption rate and that the
reduction in OCR plays a role in radiation resistance. In fact, in vitro measurements of oxygen
consumption rate revealed lower OCR in UM-SCC-47 cells in comparison to UM-SCC-22B cells
(see figure 7).
However, significant research has demonstrated the clinical value of reducing OCR to
improve treatment response by increasing the available oxygen for radiosensitization. Secomb
and colleagues showed, using theoretical simulations that utilized experimental observations, that
a reduction in oxygen consumption by only 30% was sufficient to completely abolish hypoxia
whereas a 4-fold increase in flow rate or a 11-fold increase in arterial pO2 was required to achieve
the same effect34. A comprehensive study that measured radiation-induced changes in the tumor
microenvironment in the first 24 hours proposed that early reoxygenation within tumors was likely
due to a combination of increased oxygen supply and a decrease in oxygen consumption35. The
same group showed that inhibiting mitochondrial respiration using glucocorticoids leads to a
reduction in OCR and delayed tumor growth36. A more recent study has shown that Arsenic
trioxide (As2O3) treatment leads to enhanced oxygenation through reduced oxygen consumption
in mouse transplantable liver tumors, and its combination with 10 Gy leads to significant delay in
tumor growth and extended survival37. In addition, Benej et al determined that reducing OCR
using Papaverine, a muscle relaxant and mitochondrial complex I inhibitor, significantly decreases
hypoxia, improves tumor pO2, and delays radiation-induced tumor growth38. These studies
present an interesting juxtaposition – while a reduction in oxygen consumption is clearly beneficial
in decreasing hypoxia and hence improving response rates, our work demonstrates that the
growing, relatively non-responsive UM-SCC-47 tumors are likely developing a reduced oxygen
consumption rate which is being manifested as a decrease in deoxygenated hemoglobin and
hence increased oxygenation. As discussed earlier, our previous work in a matched model of
radiation resistance showed that inhibition of HIF-1α led to a reduction in pyruvate dehydrogenase
kinase (PDK-1) content33. PDK-1 is a negative regulator of pyruvate entry into the mitochondria.
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Thus, inhibiting PDK-1 increased mitochondrial oxygen consumption and hence cell death in
radiation-resistant cells. It will be important to investigate the effects of HIF-1 inhibition in vivo to
determine if the same phenomenon can be recapitulated in tumors.
HIF-1 also plays an important role in regulating vascular radiosensitivity. Gorski et al
showed that radiation caused a large cell line-dependent increase in vascular endothelial growth
factor (VEGF) over the first 72 hours following treatment and that increased VEGF expression
promoted endothelial cell radioresistance39,40. Treatment of mice with anti-VEGF prior to radiation
therapy led to a significant reduction in tumor growth that was greater than the expected additive
effect of the two treatments. Moeller et al found that VEGF expression overlapped completely with
HIF-1 in irradiated tumors, strongly implicating HIF-1 as a major regulator of endothelial cell
radiation resistance due its regulation of VEGF24. However, our observation of increased VEGFR2 in UM-SCC-22B tumors which expressed lower levels of HIF-1α may indicate that VEGF could
have different upstream sources independent from HIF-1.
Although we did not observe any statistically significant differences in tissue scattering
between the NT and XT groups of either cell line, we did observed a significant temporal increase
in UM-SCC-22B tumors (both NT and XT) over the 14-day period. The increased scattering in the
NT group could be attributed to either increased tumor volume, which would increase cell density
and hence light scattering from cells, or an increase in tumor hypoxia. We have previously
demonstrated a strong association between tumor hypoxic fraction and tissue scattering16.
However, the temporal changes in scattering in the XT group are intriguing given the lack of
change in tumor volume or tumor oxygenation over the 14-day period and seem worthy of further
investigation.
Although diffuse reflectance spectroscopic measurements present a promising avenue for
studying radiation response in superficial tumors of skin, cervix, and oral cavity, it has limited
penetration depth and is not ideal for deep-seated tumors. Sampling depth can be improved by
using larger separations between source and detector fibers as well as by extending spectral
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boundaries to near-infrared (NIR). For example, Sunar et al have demonstrated the utility of NIRS
in monitoring chemo-radiation induced physiological changes in patients of head and neck
cancer41. In addition to greater penetration depth, NIR spectroscopy provides more quantitative
parameters because of the light absorption by lipid and water at higher wavelengths. A study by
Ohmae et al in breast cancer patients, has shown such optical measurements of lipids and water
to be highly concordant with computed tomographic measurements42. Tromberg et al have used
a combination of hemoglobin and lipid absorption as well as scattering to determine a ‘Tissue
optical index’ for predicting treatment response in breast cancer patients undergoing neoadjuvant
chemotherapy43. Multispectral optoacoustic tomography (MSOT)44–46 and photoacoustic
imaging47,48 is another technique that can provide information about hemoglobin concentration
and saturation at depths of up to 7 cm. However, despite its repeated and non-invasive
measurements of tissue physiology, MSOT-based systems are currently more expensive than
diffuse optical systems.
We also used radiation induced changes in optical properties (sO2, HbO2, dHb, cHb, µs’)
for constructing our logistic regression and leave-one-out based classifier and we are able to
differentiate local-control and treatment-failure tumors with AUC value of 0.6. Although we show
acceptable results, our accuracy in classification of responding and non-responding tumors is far
from ideal. It should be noted that similar accuracy for identification of radiation-response using
only changes in sO2 has been reported17. However, that study have used the changes in oxygen
saturation in response to larger doses of radiation in constructing their logistic regression model.
Since larger doses of radiation can cause greater reoxygenation in tumors17, changes in
oxygenation alone in their model had a similar performance to ours. Since the goal of this study
is to investigate whether optical spectroscopy combined with LR can identify tumor response while
treated with lower doses of radiation, increasing sample size in training the LR model may
increase the overall accuracy in classification of local-control and treatment-failure tumors. In
addition, we have used only hemoglobin-related parameters and scattering in training our LR
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model. However, oxygenation and structural changes may not provide a fully holistic
representation of functional differences among radio-resistant and radio-responsive tumors and
adding other biomarkers could enhance the performance of LR in classification of radioresponsive and radio-resistant tumors. While our work here and elsewhere has explored the
important role for HIF-1 in the context of oxygen consumption and metabolism in radiation
resistance, HIF-1 also affects other aspects of the tumor microenvironment, such as extracellular
matrix remodeling. We have previously used Raman spectroscopy on excised tumor xenografts
to demonstrate differences in biomolecular composition, specifically lipids and collagen, in
irradiated and non-irradiated UM-SCC-22B and UM-SCC-47 tumors49. Based on these
differences, we were able to accurately distinguish radiation-sensitive from responsive tumors.
Thus, combining diffuse reflectance and Raman spectroscopy for simultaneous monitoring of
radiation-induced functional and biomolecular changes within the tumor could improve our
understanding of microenvironmental changes related to treatment resistance. This combination
can also improve the overall accuracy in classification of radiation-resistant and -sensitive tumors.
Other studies have also shown that compared to a single optical modality, combination of optical
modalities is more accurate in discriminating healthy and diseased lesions in neoplasms of
breast50 and cervix51,52.
In summary, we have used diffuse reflectance spectroscopy to monitor tumor hemoglobin
oxygen saturation during the course of radiation therapy and found that radiation-resistant tumor
xenografts show an increase in tumor vascular oxygenation following radiation therapy, a
phenomenon not observed in radiation-sensitive HNSCC tumor xenografts. Our analysis of
oxygenated and deoxygenated hemoglobin concentrations following radiation therapy point to
decreased oxygen consumption as a likely factor in the increased reoxygenation observed in the
UM-SCC-47 tumors. In addition to providing valuable information about functional changes within
the tumor at early time points, our study also illustrates that optically determined reoxygenation
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can be translated into clinical setting and used as a biomarker for distinguishing radio-responsive
and non-responsive head and neck cancer patients.
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Tables and figures

Table 1. Tumor distribution in different groups in radiation-response study.
Cell line

Treatment

No. of
mice

No. of
tumors

UM-SCC-22B

NT

13

24

XT

24

24

NT

12

22

XT

19

19

68

89

UM-SCC-47

Total

55

Table 2. Tumor distribution in different groups for immunohistochemistry
Cell line

Treatment

Baseline

24h

48h

UM-SCC-22B

NT

7

5

5

5

5

3

3

4

4

XT
UM-SCC-47

NT
XT

4
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Figure 1. Study design for radiation-resistant and -sensitive tumors. A, Timeline for the schedule
of fractionated radiation and spectroscopic measurement. The lightning bolt signs indicate days
of each fractions of radiation. Yellow sun signs indicate acquisition of optical spectra from the
animals. On days of radiation, DRS spectra were collected immediately before and one hour after
radiation. Comparison of the survival rate for control (NT) and irradiated (XT) animals bearing
UM-SCC-22B (B) and UM-SCC-47 (C) tumors. P values based on log-rank test. Censored data
points illustrated by x sign. Tumor growth kinetics (D&E) are observed to identify radiation
response of NT and XT groups among UM-SCC-22B and UM-SCC-47 tumors. Data are
presented as group mean (line) ± SEM (semitransparent shadow). Significant differences among
NT and XT treatments in specific days are illustrated with black asterisks (*) while significant
differences of specific days with respect to their own value in day 1 are illustrated using pounds
(#). Arrows adjacent to the significance signs are indication of presence of significance until the
end of study. * and # indicate statistical significance at p<0.05.
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Figure 2. Representative DRS spectra, residuals, and extracted absorption and scattering
coefficients. DRS spectra of UM-SCC-22B (A) and UM-SCC-47 (B) tumors on day1 (red circles),
day5 (yellow squares), day10 (blue diamonds), day14 (green triangles), and their corresponding
LUT fit (black solid line). Representative spectra collected from animals in XT groups. The perfect
agreement between the measured data and their fits is also illustrated. Extracted absorption and
scattering coefficients are illustrated in figure D-F.
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Figure 3. Fold change in hemoglobin oxygen saturation sO2 (A&B), total hemoglobin
concentration cHb (C&D), oxygenated hemoglobin HbO2 (E&F), deoxygenated hemoglobin dHb
(G&H), and reduced scattering coefficient μs’ (I&J) are observed over time to identify biomarkers
of radiation-resistance. Data are presented as group mean (line) ± SEM (semitransparent
shadow). Significant differences among NT and XT treatments in specific days are illustrated with
black asterisks (*) while significant differences of specific days with respect to their own value in
day 1 are illustrated using pounds (#). * and # indicate statistical significance at p<0.05.
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Figure 4. Temporal changes in optical properties in response to 4 doses of radiation. Foldchanges in sO2 (A, B), HbO2 (C, D), and dHb (E, F) in response to 4 doses of radiation are
illustrated at 4 time points: before (gray), 1h (red), 24h (green), and 48h (blue) after radiation.
Data are presented as group mean + SEM. * and ** respectively indicate p<0.05 and p<0.01.
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Figure 5. Double-staining of Pimonidazole and HIF-1α from a representative UM-SCC-47 tumor
excised 24 hours after radiation. The acquired images were binarized using a fixed threshold.
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Figure 6. Immunohistochemical assessment of tumor hypoxia and HIF-1α in tumor tissue
sections. A, Representative images from UM-SCC-22B and UM-SCC-47 tumors excised at
baseline, 24, and 48 hours after radiation. The false-colored red and green signals respectively
represent Pimonidazole positive and HIF-1α positive pixels. The scale bar represents 250 μm.
Quantification of percentage of Pimonidazole positive and HIF-1α positive pixels in UM-SCC-22B
and UM-SCC-47 tumors at baseline (B) and following time points (C&D).
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Figure 7. Basal oxygen consumption rate measured by Seahorse metabolic flux assay according
to manufacturer’s protocol. * indicate statistically significant difference according to Wilcoxon rank
sum test. Error bars represent standard deviation from the mean of 3 plate value.
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Figure 8. Immunohistochemical assessment of VEGF-R2 in tumor tissue sections. A,
Representative images from UM-SCC-22B and UM-SCC-47 tumors excised at baseline and 1
hours after radiation. The false-colored red signal represents VEGF-R2 positive pixels. The scale
bar represents 250 μm. Quantification of percentage of VEGF-R2 positive pixels in UM-SCC-22B
and UM-SCC-47 tumors (B).
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Figure 9. Accuracy of local-control and treatment-failure classification performed by logistic
regression is presented. Daily ROC curved are generated from leave-one-out analysis.
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Chapter 4: Raman spectroscopic investigation of radiation-induced biochemical changes
in tumor microenvironment of head and neck tumor xenografts
Introduction
Tumor hypoxia and hence changes in oxygenation have been extensively studied in the
context of radiation therapy due to the role of oxygen in mediating radiation-induced cell death.
Several preclinical and clinical studies have explored the utility of using oxygen-sensing
microelectrodes1 or noninvasive diffuse optical spectroscopy2–5 (as already extensively discussed
in Chapters 1 and 2) to measure tumor hypoxia as well as radiation-induced changes in
oxygenation and hence, predict treatment outcome. However, in addition to tumor oxygenation,
radiation therapy can also induce biomolecular alterations in tumor microenvironment that might
be associated with treatment response or resistance. Such biomolecular alterations can be
measured with Raman spectroscopy (RS).
RS is an optical technique that can provide quantitative and chemically-specific
information about biomolecular changes of the host cells and tissues. RS is based on in-elastic
scattering of photon after its interaction with a vibrating molecule6. The energy difference among
the incident photon on the sample and its in-elastically scattered version is equal to the required
energy to excite the specific vibration of a specific molecule. Thus, biological molecules with
unique chemical features can be identified without exogenous dyes and changes in their content
can provide pathological information7. RS has primarily been studied within the sphere of cancer
detection and margin analysis. For example, Haka et al have used in vivo RS measurements for
intra operative margin assessment during partial mastectomy of breast cancer patients and have
shown perfect sensitivity and specificity in stratification of tumor lesions healthy normal tissue8.
Similar results have also been shown for cancers of oral cavity, cervix, and brain6,9,10. More recent
studies have utilized RS in studying radiation-induced spectral alterations in in vivo cell cultures
and ex vivo tumor samples. Yasser et al have identified spectral differences associated with

67

proteins, lipid, and nucleic acids between parental and radio-resistant sublines of oral cancer cell
lines11. Matthews et al have investigated radiation-induced biomolecular changes of glycogen
accumulation in radio-resistant cancer cells and have shown that such accumulation can be
inhibited via glycogen synthesis inhibitor, metformin12. In addition, RS application in detection of
biomolecular changes in excised radiated tumor xenografts have also been shown13,14.
In a very recent study, we investigated the utility of RS in identifying radiation-induced
changes in excised lung and head & neck tumor xenografts and observed consistent differences
in lipid and collagen content between radiation-resistant and -sensitive tumors15. Although our
results featured RS as a powerful tool in studying radiation-induced changes in tumor
microenvironment, the tumor xenografts used in our previous study were excised 35-50 days after
tumor inoculation and radiation. Here, we sought to investigate whether in vivo Raman
spectroscopy is sensitive to early radiation-induced microenvironmental alterations. To this end,
we used head and neck UM-SCC-22B and UM-SCC-47 cell lines, with known radiosensitivity16 in
formation of our tumors and treated tumor xenografts with a single dose of 2 Gy 5. We performed
in vivo Raman spectroscopy on tumors and analyzed collected Raman spectra using multivariate
curve resolution-alternating least squares (MCR-ALS) to uncover biomolecular changes within
the tumor microenvironment. We observed radiation-induced increase in lipids and collagen
respectively in radiation-sensitive and -resistant tumors. Our results underline the sensitivity of
Raman spectroscopy to early radiation-induced microenvironmental changes. Longitudinal RS
measurements that associate these changes with treatment response of individual tumors could
shed further light in microenvironmental characteristics of radiation-resistant tumors and can
potentially serve as biomarkers of radiation-response.
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Materials and Methods
Aqueous solutions
Three solutions of metabolites containing lactate, glucose, and combination of lactate and
glucose were prepared in distilled water as following. Glucose-only solution was prepared by
dissolving 500 mg of D-(+)-Glucose (G8270 – Sigma Aldrich) in 10 mL of distilled water to achieve
a concentration of 50 g/L. This concentration was chosen to represent 5% of the maximum
solubility of D-glucose in distilled water. Lactate-only solution on the other hand, was prepared by
mixing 0.414 mL (equivalent of 500 mg at density of 1.206 g/mL) of Lactic acid solution (L1875 –
Sigma Aldrich) with 10 mL of distilled water. This was performed to ensure equal concentrations
for lactate-only and glucose only solutions. Finally, to create the solution consisting of both DGlucose and Lactate, 500 mg of D-Glucose was dissolved in 10 mL of Lactic acid solution.
Cells, tumors, and radiation treatment
Cell culture conditions and tumor xenografts formation have previously been described in
chapter 2 in detail. Tumor growth of all mice were monitored daily and animals were randomly
distributed to one of the treatment (control or a single dose of 2 Gy of radiation) and time points
(Baseline, 1, 24, and 48 hours after radiation) once their volume reached 200 mm 2 (See tumor
distribution in Table 1). Treatment of 2 Gy was delivered using an X-rad 320 biological cabinet
(Precision X-Ray, North Branford, CT) while the entire animal body was covered under lead
blocks except the tumor. During radiation, mice were kept under anesthesia using a mixture of
isoflurane (1.5% v/v) and 100% oxygen. This study was approved by the Institutional Animal Care
& Use Committee (IACUC) at University of Arkansas (Protocol number: 18061).
Raman spectroscopy
Prior to in vivo Raman spectroscopic measurements, tumor bearing animals were
anesthetized and the skin tissue covering the tumor was surgically removed. Great care was
taken to prevent damaging tumor microenvironment and cause unintended bleeding. The bare
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tumor was brought into contact with a fiber-optic-probe to perform Raman spectroscopic
measurement. After acquisition of Raman spectra, tumors were excised, and animals were
euthanized. Our Raman system has been described previously15. Briefly, this system included a
diode laser emitting at 830 nm (500 mW maximum power, Process Instruments, Salt Lake City,
UT) for excitation and an imaging spectrograph (Holospec f/1.8i, Kaiser Optical Systems, Ann
Arbor, MI) with a thermoelectrically cooled CCD camera (LS 785, Princeton Acton) for spectral
acquisition. A 2 mm flexible custom-made fiber probe (EmVision LLC - Loxahatchee, FL) was
used for light delivery through an excitation fiber located at the center of the probe. The excitation
fiber was terminated with a short-pass filter which transmits laser light and attenuates longer
wavelengths. This fiber is surrounded with 15 collection fibers annularly located at approximately
800 μm away from the central excitation fiber. The collection fiber is also preceded with a longwavelength pass filter transmitting tissue’s Raman spectrum and blocking backscattered light.
Finally, a sapphire ball lens was placed after the short- and long-pass filters creating a distance
of 1 mm between the optical fibers and the ball lens to ensure collimation of the excitation light
(for reducing the incident energy and preventing tissue damage) and maximal coupling of the inelastically scattered light into the collection fibers17. The estimated sampling volume achieved by
this probe is 1 mm3. We used this setup to collect 50 Raman spectra with acquisition time of 1
second from spatially distinct locations on the tumor to account for tissue heterogeneity. For
measurements from aqueous solutions, the fiber probe was placed within the aqueous solution.
2350 spectra from 47 tumors and 2400 spectra from 3 aqueous solutions were acquired.
Data analysis
Saturated spectra and spectra contaminated with cosmic rays were visually identified and
removed from the dataset. Prior to any further processing, the wavenumber axis of the acquired
Raman spectra were shifted according to spectral peaks of 4-acetamidophenol. Further data preand post-processing was limited to only fingerprint region (600-1800 cm-1). Next, tissue
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fluorescence was removed by subjecting the recorded Raman spectra to a fifth-order polynomial
algorithm. To neutralize potential variations in laser power, baseline-corrected spectra were then
normalized such that their sum of squares is set to unity. Next, the normalized spectra were
subjected to median-filtering to remove random spikes induced by cosmic rays to avoid overlaying
of cosmic rays with biological signal. We decomposed the spectral data and recovered the
spectral profiles (loadings) and the abundance (scores) of the biochemical constituent of
biological specimen using multivariate curve resolution-alternating least squares (MCR-ALS)
without prior knowledge of the content of the specimen18. Loadings and scores were limited to
nonnegative values in decomposition of the normalized spectra through an iterative optimization
routine until convergence was achieved. All data pre-processing and analysis was conducted
using MATLAB (Mathworks, Natick, MA).
Immunohistochemistry and histology
We sliced flash-frozen tumors into sections of 10 μm using a cryostat (CM 1860; Lecia,
Inc., Nussloch, Germany). Immunofluorescence procedure has been described recently5. Briefly,
tumor sections were hydrated in PBS, fixed with 4% PFA, permeabilized using 0.5% Triton-X 100,
and incubated using an in-house blocking solution (95% PBS + 4% goat serum + 1% sodium
azide) for an hour. Next, slides were incubated with Fatty acid synthase (3180S – Cell Signaling,
Danvers, MA) antibody for 3 hours at room temperature. The slides were next tagged with Alexa
Fluor 488 goat anti-Rabbit (4412S – Cell Signaling). Immunostained tumor sections of all the
slides were imaged using a confocal microscope (Fluoview FV10i, Olympus) using a 10X
objective (UPLSAPO10X, NA = 0.4, Olympus). The microscope software enabled stitching
individual images acquired from different regions of interest (ROI) into one single image which
encompassed entire tissue section. Signal of acquired images were compared to background
intensity using histogram, and a fixed threshold was used in separating pixels containing true
signal from the background. Possible presence of non-specific binding and endogenous tissue
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autofluorescence were respectively investigated by imaging slides incubated with no antibodies
and slides incubated with secondary antibody only. Both were found to be absent. Finally,
percentage of FASN positive pixels within each tissue section was calculated by dividing
segmented pixels by the total number of tumor tissue pixels.
In addition to immunohistochemical assessment of FASN, we also performed Masson’s
trichrome staining for collagen on serial slides of same tumors. Slides were imaged using a 10X
objective on a Nikon fluorescence microscope and images acquired from different regions of
interest were stitched using Fiji – ImageJ.
Statistical analysis
We performed Shapiro-Wilk W test to identify whether MCR and immunohistochemical
data were normally distributed. The null hypothesis was rejected for both data sets. Thus,
statistically significant differences between medians of various groups were assessed based on
a Wilcoxon rank sum test. All tests employed a 2-sided p<0.05 significance level. In addition to
performing statistical analysis on MCR-scores of lipid and collagen, we used Wendt formula to
calculate the effect size of comparisons among various treatments and time points19. All statistical
analyses were performed using JMP (The SAS Institute, Cary, NC).
Results
We first sought to investigate the accuracy of MCR-ALS model in decomposition and
extraction of MCR-coefficients and -scores from Raman spectra of aqueous solutions with known
content. We made three different solutions containing Lactate (L), Glucose (G), and combination
of Lactate and Glucose (G+L, Figure 1A). Pre-processed Raman spectra of three different
solutions are illustrated in Figure 1B where each spectrum is average of 800 spectral
measurement from specific solution. Spectral averaging was performed for visualization purposes
only. Entire Raman spectral dataset were decomposed using MCR-ALS without any mathematical
manipulation (e.g. group averaging) and MCR-scores containing “pure” spectral components
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were extracted (Figure 2C). As expected, we identified only two “pure” components that strongly
resembled the characteristics of Raman spectra of Lactate and Glucose (spectral variance =
99.998%). The extracted “pure” components closely resembled Raman spectra of pure lactate
and glucose20,21. Finally, we investigated the quantitative scores of glucose and lactate from
individual measurements of L, G, and L+G solutions (Figure 2D). We observed high, low, and
intermediate lactate-related MCR-scores respectively from L, G, and L+G solutions. Furthermore,
we observed low, high, and intermediate glucose-related MCR-scores respectively from L, G, and
L+G solutions. These results indicate that based on lactate- and glucose-related MCR scores, L,
G, and L+G solutions can be accurately differentiated with MCR-ALS algorithm.
Having confirmed the accuracy of MCR-ALS algorithm in identifying the content of
solutions with no a priori information provided, we next sought to decompose spectral data
acquired from in vivo animal measurements. Raw Raman spectra of different tumor types and
treatments are shown in Figure 2A. The autofluorescence of the spectra shown here were
removed via background subtraction in pre-processing steps. Each spectral map contained > 350
spectra. Regardless of tumor type and treatment, all tumor classes show prominent peaks at 1301
cm-1 (CH vibration of lipids), 1448 cm-1 (CH2 bending modes in lipids and collagen) and 1656 cm1

(C = C stretching in lipids). Although we observed no visually identifiable spectral variations

among the four groups, we hypothesized that a subset of pixels representing specific molecular
moieties have predictive power but is lost in averaged Raman spectra among different groups of
each cell line. We next decomposed the animal Raman spectra using MCR-ALS algorithm and
obtained three ‘pure’ coefficients. Figure 2B illustrates the three MCR-coefficients that represent
key tumor constituents of control (NT) and radiated (XT) UM-SCC-22B and UM-SCC-47 tumors.
As seen in Figure 2B, MCR-coefficient B1 contains prominent peaks at 1078 cm-1, 1266 cm-1,
1301 cm-1, 1442 cm-1, and 1654 cm-1 all of which are characteristics of lipids22. MCR-coefficient
B2 contains spectral peaks at 928 cm-1, 1040 cm-1, 1251 cm-1, 1315 cm-1, 1453 cm-1, and 1661
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cm-1 which closely resemble characteristics of collagen23,24. In addition, the spectra pattern B3
contains spectral peaks belonging to combination of collagen and nucleic acid. In addition to
recovering MCR-coefficients of contributing biological moieties, we also extracted the scores
matrix (MCR-scores) that contained the weight (abundance) of each of the MCR-coefficients for
all the acquired Raman spectra. Using these scores, we then quantitatively compared the lipidand collagen-related MCR-scores of NT and XT tumors from UM-SCC-22B and UM-SCC-47
groups. We observed higher values of lipid-related MCR scores in radiated group (XT) of UMSCC-22B tumors. Although statistically significant differences were not detected, we identified an
effect size of 0.52 among these two groups indicating that 52% of XT tumors had higher lipidrelated MCR scores in comparison to NT tumors. In contrast, control and radiated UM-SCC-47
tumors had similar MCR-scores of lipid with smaller effect size (r=0.07). Similar results were
observed for collagen scores of UM-SCC-22B tumors (r=0.08). However, radiated UM-SCC-47
tumors exhibited greater collagen-related MCR scores in comparison to control tumors (r=0.37)
although no statistical significance was observed (figure 2C).
Having identified the generic differences in lipid- and collagen -related MCR scores in NT
and XT groups of different tumor types, we next sought to identify the kinetics of these changes
over the next 48 hours after radiation (Figure 3). Tumors undergoing a single dose of 2 Gy (XT –
red boxes) and control tumors (NT – gray boxes) were subjected to Raman spectral
measurements at baseline, 1, 24, and 48 hours after treatment. We observed an increase in lipidrelated MCR scores in UM-SCC-22B tumors. NT and XT groups at 1- and 24-hours post-radiation
had higher values of lipid-related MCR scores with respect to the baseline. In addition, we
observed higher lipid-related MCR scores between NT and XT groups at 1 hour and 24 hours
after radiation time points. In contrast, radiation-resistant UM-SCC-47 tumors did not exhibit
temporal changes in lipid-related MCR score although we observed larger MCR-score in XT
groups at 1 and 24 hours after radiation time points. In addition to lipids, we observed higher
levels of collagen-related MCR scores at 1 and 24 hours after radiation time points in UM-SCC74

47 tumors. However, it must be noted that we did not observe any statistically significant
differences in anytime points. In addition, due to small sample size associated with each group,
we did not perform analysis on effect size because any result can be driven by very limited number
of animals distributed to each group.
Fatty acid synthase (FASN) is a key lipogenic enzyme that is responsible for endogenous
synthesis of fatty acids25 and has been linked to radiation resistance26,27. Thus, we investigated
the presence and extent of FASN expression in our tumors in the first 48 hours after radiation.
Figure 4 presents representative images of immunohistochemical staining of FASN at baseline
and 1h after radiation in UM-SCC-22B and UM-SCC-47 tumors (A). Figure 4B illustrates the
quantification of immunohistochemical assessment of NT and XT tumors collected at baseline, 1,
24, and 48 h after a single 2 Gy dose of radiation. We noted a significant increase in expression
of FASN 1 hour after radiation in radiation-sensitive UM-SCC-22B tumors. In contrast to UM-SCC22B tumors, we observed no significant changes in expression of FASN in UM-SCC-47 tumors.
Finally, to confirm the accuracy of multivariate analysis of Raman spectra, we compared
collagen-related MCR-scores to histologically determined collagen area fraction. Figure 5A
presents a representative UM-SCC-22B tumor section stained with Masson’s trichrome and its
corresponding binarized mask. We identified a non-significant correlation between MCR-scores
of collagen with collagen area fraction (r=0.21). Both UM-SCC-22B and UM-SC-47 tumors
presented with a wide range of collagen area fraction and collagen-related MCR scores.
Discussion
Better understanding of metabolic alterations that lead to radiation-resistance is crucial for
personalization of treatment and identification of radiation-resistant tumors at early time points
after treatment commencement. Radiation resistant cancer cells exhibit altered metabolic shift
towards glycolytic28,29 and anabolic pathways26,27 to produce energy and synthesis of lipids in
order to ensure rapid tumor growth and avoid cell death. One significant driving factor for this
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glycolytic shift is hypoxia and its transcription factor, hypoxia-inducible factor-1α (HIF-1α), a
phenotype associated with higher mortality30–32 and a predictive/prognostic biomarker of radiation
response33,34. Stabilization of HIF-1 also promotes glycolytic activity35. As discussed in previous
chapter, greater HIF-1 expression as well as lower optical redox ratio (ORR) have been identified
in radiation-resistant lung cancer cell line28, a results which were reversed by chemical inhibition
of HIF-129. In addition to inducing glycolytic changes in tumors, radiation can also alter tumor
microenvironmental content. we recently used Raman spectroscopy to study radiation-induced
biochemical changes in tumor microenvironment of lung and head and neck tumor xenografts.
On ex vivo tumors excised 35-50 days after radiation, we have identified HIF-1 targets, lipid and
collagen, to be significantly higher in radiation-sensitive tumors compared with radiation-resistant
tumors15. Our long-term clinical goal is to investigate whether Raman spectroscopy can
differentiate radiation-responder and non-responder patients during the first days of treatment.
Here, we sought to test the sensitivity of label-free Raman spectroscopy to early radiation-induced
biomolecular alterations in radiation-resistant and -sensitive tumors.
We observed higher contents of lipid-related MCR-score in 1, 24, and 48 hours after
radiation in comparison to baseline in radiation-sensitive tumors. These results are supported by
a study by Deng et al, where increased lipid content was observed in radiation sensitive LNCaP
cell line compared to relatively resistant H460 and MCF7 cell lines36. In radiation-sensitive UMSCC-22B tumors, we additionally observed an increase in FASN one hour after radiation which
could be the reason for the observed major increase in lipid-related MCR scores. However,
numerous studies have shown lipogenesis inhibition via pharmacological inhibitors or RNAinhibitor mediated silencing of lipogenic enzymes, FASN and Acetyl-CoA Carboxylase-α, arrests
cell proliferation and hence, leads to cell death37–42. Rysman et al have shown that de novo
lipogenesis protects cancer cells from insults by free radicals and chemotherapeutics which can
be reversed by inhibition of lipogeness43. Furdui and colleagues have identified higher expression
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of FASN in radiation resistant rSCC-61 cells, inhibition of which results in increased cytotoxicity
and sensitivity to radiation26,27. Rae and colleagues have shown that inhibition of FASN sensitizes
prostate cancer cells to 2 Gy of radiation44. Additionally, immunohistochemically determined
FASN expression have been associated with tumor progression and survival in neoplasms of
ovary45, melanoma46, and nephroblastoma47. Bensaad et al have shown lipid droplet
accumulation in hypoxic condition to be HIF-1α dependent and its inhibition profoundly increases
ROS toxicity, delays tumor growth, and reduces cell survival48. These studies have implied that
accumulation of glycolytic intermediates is vital for cell proliferation and survival. Although our
findings are in contrast with the mentioned studies, one particular study in neoplastic lesions of
oral tongue by Krontiras et al noted that FASN expressing tumors had better survival compared
to weaker FASN expressing tumors49 which implies that the relationship between FASN
expression and radiation-response is not well-understood and deserves further investigation.
Radiation injury is known to incite an acute response by overexpressing growth factors
through macrophages that lead to recruitment and development of fibroblast and myofibroblasts
which leads to collagen secretion50,51. In addition to collagen deposition induced by radiation,
collagen has been identified to protect cancer cells against radiation. In vitro studies of renal cell
carcinoma have shown that adherence to collagen I protects cancer cells from radiation-induced
apoptosis during both normoxic and hypoxic conditions52. Collagen deposition has also been
known to be driven by hypoxia inducible factors (HIFs). In vitro studies of MDA-MB-231 breast
cancer cells have shown hypoxia to stimulate prominent collagen cross linking through HIFs,
knock downs of which abolished collagen cross linking53. These studies are consistent with our
findings because as shown in previous chapter, UM-SCC-47 non-responsive tumors have higher
content of HIF-1α5.
Because of the lack of normal distribution of MCR-scores and the fact that some of the
investigated time point were assigned with very small number of samples (i.e. n=2), we did not
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investigate radiation-induced significant differences between various time points. However,
comparison of lipid-related MCR-scores among control and radiated UM-SCC-22B tumors yielded
a p value very close to significance (p=0.052). Using Raman spectroscopy at early time points
after radiation, several studies have shown significant biomolecular differences in radiationresistant and -sensitive cells12,36. Thus, we hypothesize that increasing sample size in future
studies can identify significant biomolecular differences in vivo as well.
Although MCR-ALS has widely been used in multivariate analysis in various disciplines,
the extracted MCR-scores do not measure the content of actual species of specimen under
investigation. Thus, it is important to confirm the accuracy of these findings with controlled
experiments. To this end, we performed Raman spectroscopic measurements on aqueous
solutions with known content and identified very close agreement between a priori known
concentrations with MCR-identified contributors. To validate our in vivo MCR-findings, we
compared collagen-scores of MCR against gold-standard methods of collagen determined from
the same tumors. However, we failed to show significant and strong correlations between two
factors. In chapter 2 of this dissertation, we performed a similar study where optical findings of
tumor oxygenation were confirmed with immunohistochemical measures of hypoxia. Hypoxia on
those tumors were specifically investigated in depth of the tumor that corresponded to penetration
depth of diffuse reflectance probe. However, for tumors that were used in current study, we failed
to track the tumor depth in which histological slides were obtained and hence, there is a very
strong possibility that the collected slides were harvested from deeper layers of tumor. This could
explain the lack of strong correlation between the two parameters. Thus, any future studies that
aim to compare optical findings with tumor histology must ensure to collect slides exactly from the
depths that associate with penetration depth of utilized probe.
Other forms of imaging modalities namely, coherent anti-stokes Raman scattering (CARS)
and stimulated Raman scattering (SRS) have been used in study of lipid droplets and their role in
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cancer progression and metastasis54,55. We are particularly intrigued by a study by Zhang et al in
which SRS was been used to investigate the role of lipid droplets in different metabolic events i.e.
lipogenesis vs. lipolysis56. However, Raman spectroscopic measurements are sensitive to
vibrational modes of numerous other molecules which may contain pathological information about
radioresistant phenotype. For example, Matthews et al have shown radiation resistant cancer
cells to have higher content of glycogen which its pharmacological inhibition results in increased
radiosensitivity12. Other studies have also suggested that the synthesis of glycogen to be induced
in hypoxic conditions through HIF-1 and the accumulation of the glycogen promotes cancer cell
survival when exposed to glucose-free medium57.
In summary, we have used Raman spectroscopy to observe radiation-induced
biomolecular alterations in the first 48 hours after a single dose of 2 Gy and identified. Multivariate
analysis of acquired Raman spectra revealed increase in lipid and collagen content respectively
in radiation-sensitive and -resistant tumors. In a recent study, we have identified higher content
of HIF-1α in UM-SCC-47 tumors with respect to UM-SCC-22B tumors in 1 hour after radiation5.
We reason that the higher content of HIF-1α and FASN in these tumors could be responsible for
the observed increase in lipid content. Our future studies include genetic alteration of the
pathways that contribute to fatty acid synthesis and collagen breakdown to determine if
modification of these pathways lead to corresponding changes in MCR-derived spectral
components. Longitudinal confirmatory studies with promising results can open the path for
clinical translation of Raman spectroscopy where specific biomolecular-changes can be used as
a biomarker of radiation-resistance.
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Tables and figures
Table 1. Tumor distribution in different groups. NT and XT respectively represent control and
radiated animals.
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Figure 1. MCR-ALS analysis of aqueous solutions with known content. A, 800 Raman spectra
from Lactate-only, Glucose-only, and combined Lactate and Glucose solutions. B, Average
Raman spectra from three different solutions. Standard deviations from group average were
smaller than the lines and hence, are not visible. C, MCR-coefficients extracted from the MCRALS algorithm. D, MCR-scores of lactate and glucose of individual Raman spectra from 2400
spectral measurements.
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Figure 2. Spectral decomposition of Raman spectra using MCR-ALS algorithm. A, Average
Raman spectra ± 1 standard deviations from group mean (transparent shadow) collected from
NT and XT treated radiation-resistant (UM-SCC-47) and radiation-sensitive (UM-SCC-22B) head
and neck tumor xenografts. B, MCR-coefficients derived from raw Raman spectra. B1 and B2
respectively represent lipid-rich and collagen-rich loadings. B3 represents a loading that contains
spectral features from combination of weak collagen and nucleic acid. C, Boxplots illustrating the
scores of lipid-rich and collagen-rich coefficients in UM-SCC-22B (left panel) and UM-SCC-47
tumors (right panel). Outliers are <10% data from each group. No significant differences were
observed using Wilcoxon rank sum test. The effect size (r) also provided.
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Figure 3. MCR scores of UM-SCC-22B and UM-SCC-47 tumors at different time points after
radiation. Boxplots illustrating the scores of lipid-rich and collagen-rich coefficients in UM-SCC22B (left panel) and UM-SCC-47 tumors (right panel). Outliers in each group illustrated using
asterisks with highest percentage of outliers (15%) observed in 1H-NT group. Effect sizes are
provided for each comparison. Statistical analysis not performed because of presence of n=2
samples in some of time points.
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Figure 4. Immunohistochemical assessment of FASN in tumor tissue sections. A, Representative
images from UM-SCC-22B and UM-SCC-47 tumors excised at baseline and 1 hours after
radiation. The false-colored green signal represents FASN positive pixels. The scale bar
represents 250 μm. B, Quantification of percentage of FASN positive pixels in UM-SCC-22B and
UM-SCC-47 tumors.
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Figure 5. A, Representative UM-SCC-22B tumor stained with Masson’s Trichrome and its
corresponding binarized version. White pixels indicate collagen-positive regions. The scale bar
represents 1 mm. B, Scatter plot representing the association between histologically-determined
collagen fraction and collagen-related MCR scores in UM-SCC-22B (red stars) and UM-SCC-47
(blue inverse triangle) tumors. Symbols include tumors excised before, 1h, 24, and 48 hours after
radiation. Black solid line indicates the regression line.
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Chapter 5: Conclusion
Summary
This dissertation used diffuse reflectance and Raman spectroscopy to investigate the
association

between

radiation-induced

physiological

and

biomolecular

changes

with

radiosensitivity of the employed tumors. These studies were carried out on tumor xenografts that
were inoculated with two human head and neck cancer cell lines, UM-SCC-22B (isolated from
radiation-sensitive sensitive tumor) and UM-SCC-47 (isolated from a radiation-resistant tumor),
to represent various radiosensitivity of head and neck tumors that is observed in head and neck
oncology.
Because tumor hypoxia has long been linked to poor radiation-response, we first
investigated the association between diffuse reflectance spectroscopic measurements of oxygen
saturation with tumor hypoxia. We showed optically determined oxygenation is negatively
correlated with tumor hypoxic fraction and hence can serve as a negative indicator of tumor
hypoxia. Next, we investigated whether physiology of radiation-resistant and -sensitive tumors
are altered differently in response to radiation and identified measurable differences in
reoxygenation kinetics of radiation-resistant and -sensitive tumor xenografts in pre-clinical animal
models. Based on radiation-induced changes in optical properties, we trained a logistic regression
model that is capable of classifying treatment failure and local control tumors. Although the
observed accuracy and the area under the curve associated with the model is not ideal, we believe
that the addition of Raman spectroscopy can greatly improve the overall accuracy of the model
by providing quantitative measures of both functional and biomolecular changes in the tumor
microenvironment. Thus, investigating additional features (e.g. radiation-induced biomolecular
changes) can improve our understanding of radioresistant-phenotype and improve our ability to
identify responding and non-responding tumors.
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Raman spectroscopy has previously been shown to identify different biomolecular
composition, specifically lipids and collagen, in radiation-resistant and -sensitive tumors that were
excised 25-30 days after radiation1. However, it is not clear whether in vivo measurements at
early time points after radiation can identify different biomolecular changes among radiationresistant and -sensitive tumors. Thus, to study radiation-induced biomolecular changes in tumor
microenvironment and the association of these changes with tumor radiosensitivity, we performed
in vivo Raman spectroscopy on radiation-resistant and -sensitive tumors in the first 48 hours after
radiation. We observed difference in the spectral scores of lipid and collagen respectively in
radiation-sensitive and -resistant tumors. These results indicate that Raman spectroscopy can
detect biomolecular changes between radiation-resistant and -sensitive tumors as early as 48
hours after radiation and can potentially serve as biomarkers for identification of radiationresistant and -sensitive tumors.
Future studies include simultaneous measurements of diffuse reflectance and Raman
spectra with the goal of characterizing radiation-induced reoxygenation and biomolecular
changes in head and neck cancer patients. These two modalities will be combined by engineering
novel spatially-offset probe that can be used to access tumors of oral cavity or delivered to tumors
of pharynx and larynx thru the working channel of flexible laryngoscopes (Figure 1). Prior to
initiation of treatment on these patients, baseline RS and DRS spectra will be acquired.
Subsequent optical measurements will be performed on following days after each dose of
radiation and kinetics of oxygenation and biomolecular contents will be associated with radiation
response. We envision that performing combined diffuse reflectance and Raman spectroscopic
measurements on numerous responding and non-responding patients can help us develop
artificial intelligence-based-model that based on only baseline measurement, can identify
radiation-responsive and non-responsive HNSCC patients.
However, prior to initiation of clinical trials, feasibility studies for measurements of diffuse
reflectance, Raman spectra, and their combination can help us optimize measurement protocols,
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and modify software and hardware of these systems. One such feasibility study has already been
initiated in otolaryngology department of University of Arkansas for Medical Science Winthrop P.
Rockefeller Cancer Institute. The objective of this single-arm observational study is to investigate
the feasibility of using diffuse reflectance spectroscopy for measuring optical properties of 10
patient tumors that are located inside the oral cavity. Three optical spectra will be collected from
the diseased tonsil, the contralateral healthy tonsil, and a normal tissue site on the buccal mucosa.
The acquisition of control spectra from normal tissue will allow normalization of each tumor
spectrum to the patient’s normal tissue, and significantly reduce inter- and intra-patient variability.
The acquisition of spectra from contralateral healthy tonsil will serve as a control measurement
that represents functional properties of healthy tonsil. Patients with tumors on both tonsils and
patients who have undergone any form of treatment or surgery will be excluded from this study.
Success metrics defined for this study includes the acquisition of optical spectra with a high signal
to noise ratio (of at least 100) that can be fit to our data analysis models to extract meaningful
endpoints, such as total hemoglobin, vascular oxygenation, and tissue scattering in at least 80%
of the patients enrolled in the study. So far, we have recruited 6 Caucasian male tonsil cancer
patients with average age of 50. However, the employed LUT model was able to fit only half of
the acquired spectra. Table 1 presents the distribution of successful fits across different patients
and measurements sites. Figure 2A illustrates representative diffuse reflectance spectra collected
from diseased tonsil (black solid), contralateral healthy tonsil (black dashed line), normal buccal
mucosa (black dashed-dot line), their corresponding LUT fits (red solid line), and their
corresponding chi-squared values. As seen in the figure, the LUT failed to successfully fit the
spectra collected from normal buccal mucosa. Quantification of accepted fits from all three sites
among 6 patients yielded high values of vascular oxygenation for spectra collected from tissue
sites (figure 2B). However, as mentioned earlier, the LUT was not able to fit half of the collected
spectra. We strongly believe this is driven by the lack of proper contact between optical probe
and the tissue at the time of data acquisition. We continue to work with our physician collaborators
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in optimizing our data acquisition protocol that guarantees data acquisition when probe is in
complete contact with the tissue. However, such success may never be achieved due to lack of
visibility of the probe-tumor interface inside upper aero-digestive tract. An alternative solution can
be the use of optical probe equipped with pressure or proximity sensors that automatically triggers
acquisition of spectra as soon as the probe comes into contact with the tumor 2. Such measures
can eliminate the uncertainties of data acquisition and pave the way for initiation of large-scale
clinical trials where combined diffuse reflectance and Raman spectroscopy can be used for
monitoring radiation-response of head and neck cancer patients.
Future work
Diffuse optical spectroscopy is a powerful technique that is capable of non-invasive
monitoring of tumor physiology and thanks to its short integration time, is ideal for accessible
tumors of oral cavity. Our pre-clinical study on tumor xenografts identified reoxygenation
phenomena in radiation-resistant tumors, which combined with other immunohistochemical
proofs, suggested that OCR reduction in response to radiation is the driving factor for
radioresistant phenotype. However, numerous studies have identified reducing OCR as a strategy
in improving treatment response3–7. Thus, several important questions remain unanswered: Does
the sequence of HIF-1 inhibition and OCR reduction carries significance? How do they affect
reoxygenation kinetics and how do they differ in radiation-resistant and -sensitive tumors? To
answer such questions, kinetics of reoxygenation, OCR, and HIF-1 content (respectively using
DRS, seahorse assay, and western blot or immunohistochemistry) induced by radiation alone,
combined with HIF-1 inhibitor, combined with OCR reducing agents, and combined with both
treatments in various sequences should be monitored to shed additional light about the relevance
of these pathways to radiation-resistance. Acquired optical properties can also be used for
classification purposes. Thus, gathering larger dataset can also be beneficial in terms of training
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of various machine learning algorithms for accurate classification of local-control and treatmentfailure tumors.
We and others have extensively utilized diffuse reflectance spectroscopy in pre-clinical
and clinical in vivo studies and hence, have a solid understanding of the setup, models used for
simulating light-tissue interaction, and the association between probe geometry, wavelength, and
penetration depth. In contrast, Raman spectroscopy has been investigated to a lesser extent in
biological tissue and deserves detailed studies before its clinical translation. For example,
multilayer tissue stimulating phantoms with known content and concentrations can provide a
better understanding in terms of whether Raman spectroscopic measurements provide a depth
averaged reading of sample. Accurate measurement of penetration depth can also be helpful in
designing spatially-offset probes that can later be used for longitudinal in vivo studies where
treatment response of individual animals can be monitored. In addition to depth penetration, such
experiments can uncover the accuracy of MCR-ALS algorithm in determining sample
constituents. Alternatively, tumors with known specific microenvironmental characteristics can be
utilized to pursue such studies. For example, using B16.BL6 murine melanoma cell line which
presents increased MMP9 expression, we can expect to observe lower collagen content
determined by Raman spectroscopy combined with MCR-ALS algorithm. This can provide a
controlled method to validate the sensitivity of the Raman spectroscopy and MCR-ALS algorithm
to specific biomolecular constituents of tissue.
Although our in vivo Raman spectroscopic studies uncovered early radiation-induced
changes in lipids and collagens, additional studies can shed light on biological pathways that lead
to observed biomolecular changes. For example, pharmacological and/or RNA mediated
inhibition of HIF-1 and FASN can provide valuable information on differential pathways that
radiation-resistant and -sensitive tumors take. One intriguing way to study the effect of modulating
these pathways is window chamber model of cancer because it enables gathering additional
information such as tumor oxygenation using hyperspectral imaging and tumor redox state using
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nonlinear two photon microscopy. Alternatively, these studies can be pursued at the cellular level
since they lack the complexity of dynamic tumor microenvironment and hence, result
interpretation become less challenging.
Finally, longitudinal and simultaneous monitoring of animals using combination of in vivo
DRS and Raman spectroscopy will enable us to correlate the observed radiation-induced
physiological and biomolecular changes with treatment outcome and hence, will provide better
understanding with possible pathways involved in radiation-resistance. In addition, combination
of these modalities will enable us with identifying the earliest time point at which diffuse reflectance
spectroscopy, Raman spectroscopy, or their combination can accurately classify treatment
responders and non-responders.
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Tables and figures
Table 1. Tumor distribution in different groups. NT and XT respectively represent control and
radiated animals.
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Figure 1. Delivery of combined Diffuse reflectance and Raman spectroscopic probe to tumor. For
tumors located in upper aero-digestive tract (i.e. larynx, pharynx, etc.) the probe will be inserted
into working channel of an NET laryngoscope.
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Figure 2. A. Representative DRS spectra acquired from diseased tonsil, contralateral healthy
tonsil, normal buccal mucosa, and their corresponding LUT fits. B. Quantification of oxygen
saturation from different tissue sites. Bars and error bars respectively represent mean and
standard deviation of the mean.
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